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ABSTRACT

BURDEN OF ILLNESS AND PHARMACOECONOMIC EVALUATION OF
LUMACAFTOR/IVACAFTOR IN CYSTIC FIBROSIS

By
Pratyusha Vadagam
December 2017

Thesis supervised by Dr. Khalid M. Kamal
Objectives: (1) To estimate the burden of illness in cystic fibrosis (CF) using 2010-2014
Medical Expenditure Panel Survey (MEPS) data, and (2) to conduct a pharmacoeconomic
evaluation of lumacaftor/ivacaftor in the treatment of CF.
Methods: The study was conducted in two parts. Part 1 involved a retrospective analysis
using individuals in MEPS database with an International Classification of Diseases,
Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis code of 277.00 for a
principal diagnosis of CF. Dependent variables were cumulative and out-of-pocket
(OOP) expenditures and independent variables included patient demographics and
clinical characteristics. Unweighted and weighted estimates of expenditure in CF group,
and an incremental cost burden in CF group compared to non-CF group was estimated. In
Part 2, static decision models were developed using MS Excel® to evaluate the cost
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effectiveness and budget impact of lumacaftor/ivacaftor over a 1-year time frame from a
payer perspective. Model inputs included drug costs (wholesale acquisition costs from
2015 Redbook), drug administration/monitoring costs from package inserts, Centers for
Medicare and Medicaid 2016 Physician Fee Schedule and published literature,
percentage predicted forced expiratory volume (FEV1% predicted) and pulmonary
exacerbation values from TRAFFIC and TRANSPORT clinical trials and cost to treat
pulmonary exacerbations from published literature. The outcomes in the CEA included
total cost of therapy, average cost effectiveness ratio (ACER) defined as cost per FEV1%
predicted and incremental cost effectiveness ratio (ICER) defined as difference in the
ratio of cost per FEV1% predicted of lumacaftor/ivacaftor and placebo. Outcomes in the
BIA included total budget impact, cost per member per month (PMPM) defined as total
budget impact per hypothetical plan population, and cost per treated member per month
(PTMPM) defined as total budget impact per target CF population. All costs were
adjusted to 2016 dollars and one-way sensitivity analyses were conducted to test the
model robustness given uncertainty in model inputs and study assumptions
Results: The average annual cost of CF care in the US between 2010-2014 was
approximately $44,600, with prescription medications being the highest cost contributor.
The mean cumulative expenditure in children with CF was $13,990 compared to
$3,231.27 non-CF group, whereas in adults with CF it was $16,975.80 compared to
$8,859.87 in non-CF group. The annual cost of therapy per patient due to
lumacaftor/ivacaftor was $379,780.11 in 2016. The ACER in patients treated by
lumacaftor/ivacaftor was $151,912.044 while the ICER compared to a placebo was
$95,016.28 per FEV1% predicted. The annual total budget impact due to inclusion of
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lumacaftor/ivacaftor on the health plan formulary was $266,045.59. The PMPM cost was
$0.022 and the PTMPM cost was $6.2067.
Conclusion: The systematic assessment of incremental CF costs and its impact on the
society is essential in increasing the awareness of decision makers to implement
intervention strategies that are effective in lowering the disease incidence and the overall
cost of disease management. In CF patients, lumacaftor/ivacaftor has demonstrated better
clinical effectiveness compared to placebo alongside an increased drug acquisition cost.
However, the therapy may be a viable alternative to existing standard therapy over a
short-time horizon. Healthcare payers, both private and public, need to evaluate the cost
effectiveness and the financial impact when considering expansion of new drug coverage
in CF management.
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CHAPTER ONE: BACKGROUND

INTRODUCTION
Cystic fibrosis (CF) is a chronic, progressive, genetic disease, which primarily affects the
respiratory, digestive and reproductive organ systems in both children and adults. 1 In CF,
cells that produce mucus, sweat and digestive juices are impaired, resulting in secretion
of thick and sticky mucus leading to breathing difficulty or even fatal lung infections over
time (Refer Figure 1). 2 Sweat and mucus play an important role in regulating the
temperature and lubrication of respiratory, digestive, reproductive systems, and in
protecting the organ systems from infection and drying. In the lungs, the abnormally
thick mucus clogs airways and traps bacteria leading to extensive lung damage and an
eventual respiratory failure. In the pancreas, mucus prevents the release of digestive
enzymes that help in the break down food and absorption vital nutrients, obstructing
digestion process. 3
Based on the diagnosis criteria, CF can be categorized into classic and non-classic types.
In classic CF, the patient demonstrates clinical disease in one or more organ systems such
as the pancreas, upper and lower respiratory tracts, male reproductive tract and has
elevated sweat chloride levels (≥60 mmol/L). Non-classic CF is usually seen in 2% of the
patient population and is characterized by normal or intermediate sweat chloride levels.
In non-classic CF individuals, the diagnosis depends upon DNA analysis which involves
identification of two copies of a disease-causing mutation in the cystic fibrosis
transmembrane conductance regulator (CFTR) gene on each parental allele or the
measurement of nasal potential difference (NPD). 4

1

Figure 1: Healthy lung vs. cystic fibrosis affected lung

Source: Mayoclinic.org, 2016

2

2

The NPD test is used to measure the voltage across the nasal epithelium by measuring
sodium and chloride transport in secretory epithelial cells through assessment of transepithelial bioelectric properties which reflect CFTR function. 5

Cause
Genes are located on chromosomes within the cell nucleus and provide instructions for
the cells to make proteins. Every human being has 46 chromosomes, with 23 inherited
from each parent. Each of the 23 pairs of chromosomes contains a complete set of genes
and every individual has two sets (one from each parent) of genes for each function. In
some individuals, the basic building blocks of a gene (called as base pairs) are mutated. A
mutation can cause the body to make a defective protein or no protein at all, resulting in
the loss of essential biological functions and eventually resulting in diseases. CF is one
such disease which is caused due to defects in CFTR gene. 6
CFTR gene is present on human chromosome 7 and is made up of 25,000 DNA
nucleotides. As in every human gene, the DNA sequence is transcribed into a messenger
molecule called mRNA. The CFTR gene has 27 segments called exons that are spliced
together to make the complete mRNA message. The mRNA message is then translated
into a chain of amino acids. This amino acid chain folds up into the correct 3-dimensional
shape to produce CFTR protein. 7
The CFTR protein functions as a channel across cell membrane that produces various
secretary fluids and digestive enzymes and transports negatively charged particles called
chloride ions into and out of cells. The transport of chloride ions helps in controlling the
movement of water in tissues, necessary to produce thin, freely flowing mucus. Mucus is
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a slippery substance that lubricates and protects the lining of the airways, digestive
system, reproductive system and other organs and tissues. The CFTR protein also
regulates the function of other channels that transport positively charged sodium ions
across cell membranes. These channels are necessary for the normal functioning of
organs such as the lungs and pancreas. 8
The mutations in CFTR gene affect the composition of mucous layer lining the epithelial
cells in the lungs and pancreas. The disruption of ion transport affects the amount of
water and texture of mucus in cell linings of lungs (Refer Figure 2).
There are more than 1700 mutations that are known to affect CFTR gene and can be
classified based on their effect on the CFTR protein (Refer Table 1). Some conditions
caused by two CFTR mutations might lead to only mild lung disease with or without
affecting the pancreas. These conditions can be described as atypical or non-classic CF.
Other disease conditions which do not meet the usual diagnostic criteria for classical CF
are referred to as CF-related disease. For example, congenital bilateral absence of the vas
deferens can cause sterility in males. 8 The most common CFTR mutation is a deletion of
three DNA nucleotides, which leads to the deletion of an amino acid (phenylalanine) at
position 508 of the protein sequence. This is denoted as phe508del mutation (F508), and
is found in around 90% of patients with CF.
Classes I, II and III mutations, presented in Table 1, generally lead to complete loss of
function and cause more severe disease. Classes IV and V cause reduction in function
and have a milder effect.

4

Figure 2: Normal lung vs. cystic fibrosis lung airways

Source: Genetics and nutrition
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Table 1: Classification of cystic fibrosis transmembrane conductance regulator
gene mutations
Class Effect on CFTR protein

Example of mutation

I

Shortened protein

W1282X. Instead of inserting the amino acid
tryptophan (W), the protein sequence is
prematurely stopped (indicated by an X).

II

Protein fails to reach cell
membrane
Channel cannot be
regulated properly

ΔF508. A phenylalanine amino acid (F) is deleted

Reduced chloride
conductance
Reduced due to incorrect
splicing of gene

R117H. Missense

III

IV
V

Source: Genetics and nutrition

G551D. A “missense” mutation: instead of a
glycine amino acid (G), aspartate (D) is added

3120+1G>A. Splice-site mutation in gene intron 16

7

6

The most common CFTR mutation identified was F508del mutation occurring in
approximately 87% of CF patients reported in 2015 CF Patient Registry Annual Report.
Of the 87%, homozygous F508del mutation accounted for about 46%. The other
commonly occurring mutations were G542X mutation (4.6%) and G551D mutation
(4.4%). All the other mutations account to less than 4%.

Disease inheritance
CF is an autosomal recessive disorder where children inherit altered genes from one or
both parents. In CF, each parent carries one abnormal and one normal CF gene but they
do not show any evidence of the disease because the normal CF gene dominates the
abnormal CF gene. 1 The disease can be inherited in two ways:
i) If two copies of the defective CF gene are inherited (one copy from each parent) they
are called CF patients. For this, both parents must have at least one copy of the defective
gene.
ii) People who inherit only one copy of the defective CF gene are called carriers and they
do not have the disease. Each time two CF carriers have a child, the chances are:


25 percent (1 in 4) the child will have CF



50 percent (1 in 2) the child will be a carrier but will not have CF



25 percent (1 in 4) the child will not be a carrier and will not have CF (Refer
Figure 3).

Most genetic tests only screen for the commonly occurring CF mutations. Hence, the
tests may sometimes falsely indicate a person as not being a carrier while they are
carriers for the disease 6

7

Figure 3: Inheritance of cystic fibrosis

Source: National Institutes of Health

6

8

Disease progression
The disease begins with reduced CFTR protein activity at the epithelial cell surface. This
then leads to a cascade of altered lung physiology including altered inflammatory
response leading to cell inflammation, obstruction, infection of lungs and airway surface
liquid (ASL) depletion, leading to defective mucociliary clearance. All these events
enhance disease progression and eventually lead to death. 9, 10

Risk factors for disease progression
The only risk factor for getting CF is having parents with abnormal CF genes who pass
the altered genes to their children. However, beyond genetic control, there are many
factors that influence the severity of the disease and yet, there is still no clear evidence
for understanding the influence of genetic and environmental factors on disease
outcomes.

11

People with CF need to consume a very large number of calories to maintain weight and
growth which can be difficult to achieve. Physical activity also helps in keeping lungs
healthy. People with CF should not smoke or be exposed to second hand smoke, as it will
worsen lung disease. They should also be careful with alcohol intake and it should be
completely avoided in case of liver disease. CF also worsens with age. CF patients
usually experience a small decline in lung function each year. Table 2 shows examples of
how different pairs of mutations in the CFTR gene affect clinical outcomes.

9

Table 2: Some possible cystic fibrosis transmembrane conductance regulator allele
genotypes and disease severity
Genotype
(Combination of
CFTR alleles)
Wild-type / Wild-type
∆508F / ∆508F
R117H / R117H

Description

WT / ∆508F
WT / 3120+1 G>A
∆508F / W1204X

heterozygote
heterozygote
compound
heterozygote
compound
heterozygote
compound
heterozygote

R553X and W1316X
591∆18 / E831X

homozygote
homozygote
homozygote

Source: Genetics and nutrition

Possible symptoms (these can vary
depending on modifier genes and
environmental factors)
Unaffected
Severe lung disease, pancreatic insufficient
Congenital bilateral absence of the vas
deferens, No lung or pancreas disease.
Unaffected
Unaffected
No lung disease, pancreatic insufficient
Mild lung disease, pancreatic insufficient
No lung or pancreas disease, nasal polyps

7
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Other risk factors associated with an increased risk of future lung disease progression for
all age groups include young age, high lung function, female sex, certain CFTR
genotypes and modifier genes, pancreatic insufficiency, poor nutritional status, lower
socioeconomic status, respiratory viral infections, infection with Pseudomonas
aeruginosa or Burkholderia cepacia and diabetes mellitus. Low weight-for-age and
height-for-age percentiles, presence of crackles, Pseudomonas infection, daily sputum,
cough and clubbing at age 3 were associated with lower FEV1 values at 6 years of age. 12

Severity
Beyond genetic control, all CF patients have individual disease courses of severity and
symptomology. Severity of pathophysiologic consequences associated with CF is
influenced by the extent to which CFTR activity is reduced. Individuals carrying a single
CFTR mutation (CF carriers) have reduced CFTR protein activity on cell surfaces
(~85%) but are unaffected. People with CF (those carrying two mutant CFTR alleles)
with one mutation retaining residual (but reduced) CFTR function have less aggressive
disease phenotypes and better overall survival than those who carry two CFTR mutations
resulting in little or no CFTR activity. 9

Assessing severity of disease
Forced expiratory volume in 1 sec (FEV1) and the fraction of FEV1 present in a CF
patient compared to a reference population (FEV1% predicted or percent predicted FEV1)
can be used to assess CF lung disease progression and survival. 11 The FEV1 is defined as
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the volume of air forcefully exhaled in 1 second. FEV1% predicted is defined as FEV1%
of the patient divided by the average FEV1% in the population for individuals of similar
age, sex and body composition. 13 The progression of lung disease in CF patients can be
described by plotting their FEV1% predicted throughout their lifetime but it may not be
reliable for children under 6 years of age because FEV1% predicted is not reliably
collected before age 6. 12 As lung disease progresses with age, FEV1% predicted
decreases. 14,15

Stages of CF disease
Severity of illness is assessed by the percentage predicted FEV1 (FEV1% predicted), with
FEV1% predicted >70%, 40%-69% and <40% categorized as mild, moderate and severe
CF, respectively. 16 Disease severity can also be influenced by age. Patients with a severe
lung disease phenotype are at greater risk for mortality at a younger age, whereas those
with a mild disease phenotype are more likely to survive to older ages.

DIAGNOSIS
CF diagnosis involves multiple steps. A complete diagnostic evaluation for CF involves a
newborn screening, sweat chloride test, prenatal test, a genetic or carrier test and a
clinical evaluation. 17
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New born screening
Newborn screening (NBS) is a nationwide program used to identify health conditions
including CF. It is usually done in the first 2 to 3 days after birth and involves a genetic
test or a blood test. A blood sample is tested for the levels of immunoreactive trypsinogen
(IRT) released by pancreas. Higher levels of IRT indicate abnormal functioning of
pancreas. But, a newborn's IRT levels may also be increased due to premature birth or a
stressful delivery. Hence, other confirmatory tests like genetic tests which report faulty
CFTR genes in newborn are warranted. 18

Sweat chloride test
Sweat chloride test is very important to diagnose CF. It measures the amount of salt in
sweat with the help of an electrode by producing mild electric current. CF diagnosis is
confirmed by high levels of salt in sweat. 19

Prenatal test
Prenatal genetic tests are done on pregnant women to check if the fetus has CF. A sample
of fluid is collected from the uterus and checked for the CFTR genes. 18

Genetic test/Carrier test
A genetic or carrier test is conducted by testing a sample of blood or saliva for faulty
CFTR gene. Genetic testing usually detects faulty CF genes in 9 out of 10 cases. 18

13

Clinical evaluation
Clinical evaluation involves a chest x ray to check for the inflammation or air trap in
lungs, a sinus x ray to check for signs of sinusitis, sputum culture to check for bacterial
growth and lung function tests to check for FEV1 levels and lung functioning. 18

SYMPTOMS
Symptoms of CF vary with disease severity. Even in the same person symptoms may
worsen or improve with time where as some people may not show any symptoms until
adulthood (Refer Figure 4).

Respiratory system signs and symptoms 20
Thick and sticky mucus associated with CF clogs the tubes that carry air in and out of the
lungs leading to
•

A persistent cough that produces thick mucus (sputum)

•

Wheezing

•

Breathlessness

•

Exercise intolerance

•

Repeated lung infections

•

Inflamed nasal passages or a stuffy nose 19

14

Figure 4: Symptoms of cystic fibrosis individuals at diagnosis reported in Cystic
Fibrosis Patient Registry

Source: Cystic Fibrosis Foundation Patient Registry, 2015 21

15

Digestive system signs and symptoms 20
Mucus can also block tubes that carry digestive enzymes from pancreas to small intestine
hindering the absorption of nutrients leading to
•

Foul-smelling, greasy stools

•

Poor weight gain and growth

•

Intestinal blockage, particularly in newborns (meconium ileus)

•

Severe constipation 19

Reproductive system signs and symptoms
Men with CF are infertile as they are born without a vas deferens. Women with CF may
have issues related to pregnancy because of mucus blocking the cervix. 19

COMPLICATIONS

Respiratory system complications 19, 20
•

Damaged airways (bronchiectasis)

•

Chronic infections

•

Growths in the nose (nasal polyps)

•

Coughing up blood (hemoptysis)

•

Pneumothorax

•

Respiratory failure

•

Acute exacerbations

16

Digestive system complications 19, 20
•

Nutritional deficiencies

•

Diabetes

•

Blocked bile duct

•

Intestinal obstruction

•

Distal intestinal obstruction syndrome (DIOS)

Other complications 19, 20
•

Thinning of the bones (osteoporosis)

•

Electrolyte imbalances and dehydration

TREATMENT
As there is no definitive cure for CF, the goals of current therapy focus on delaying
disease progression, reduction of pulmonary exacerbations, relief of chronic symptoms
and improving the patient’s quality of life. 22 Aggressive and complex treatments
including a daily administration time that range from 1 to 2.5 hours, is warranted to
achieve these goals. 22 CF treatment includes air way clearance techniques, oral and
inhaled medications, exercise and good nutrition. Airway clearance techniques (ACTs)
loosen thick, sticky mucus and it can then be cleared from the lungs by coughing or
huffing. Clearance of airways decrease lung infections and improve lung function. Chest
physiotherapy involving percussion (clapping) or vibration may also be useful to loosen
mucus from the walls of airways.

17

Medications
Medications are prescribed as maintenance therapy to clear lungs and to prevent or fight
infections in CF treatment. Existing maintenance therapy includes inhaled oral and
intravenous antibiotics (penicillins, cephalosporins, sulfa drugs, aminoglycosides,
macrolides, tetracyclines, quinolones, vancomycin, linezolid, imipenem and meropenem,
aztreonam), mucous thinners (hypertonic saline, dornase alpha), bronchodilators
(albuterol, salmeterol), corticosteroids (fluticasone, prednisone), nonsteroidal antiinflammatory drugs (ibuprofen) and other drugs like enzyme replacement therapy
(Creon® or Pancreaze®) are also used.
Currently, the newer CFTR modulators are being used as disease modifying therapies.
The disease modifying therapies correct the function of the defective protein made by the
CF gene and they target specific mutations of the CFTR gene.23 There are currently two
US Food and Drug Administration (FDA) approved CFTR modulators: ivacaftor
(Kalydeco®) and lumacaftor/ivacaftor (Orkambi®). Ivacaftor acts by facilitating chloride
ion transport and by potentiating the channel-open probability (or gating) of the G551DCFTR protein. 24 The F508del mutation of CFTR results in protein misfolding and causes
a defect in cellular processing and trafficking, thereby reducing the quantity of CFTR at
the cell surface. Lumacaftor acts by improving the conformational stability of F508delCFTR, resulting in increased processing and trafficking of mature protein to the cell
surface. 25 Both lumacaftor and ivacaftor act directly on the CFTR protein and are called
CFTR potentiators. (Refer Table 3)
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Table 3: Cystic fibrosis transmembrane conductance regulator modulator therapies, ivacaftor and lumacaftor/ivacaftor
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Drug

Category

Initial US
approval

Indication

Dose

Annual cost
(WAC)

Ivacaftor*

CFTR potentiator

2012

For patients age
6 years and older
who have
G551D mutation
in CFTR gene

One 150 mg tablet Q12
hours PO with fat-containing
food

$311,501.42

Lumacaftor/ivacaftor#

CFTR potentiator

2015

For patients age
6 years and older
who are
homozygous for
the F508del
mutation in the
CFTR gene

Age 12 years and older: two
tablets (each containing
lumacaftor 200 mg/ivacaftor
125 mg) Q12 hours PO12
hours PO
For patients age 6 years
through 11 years: Two
tablets (each containing
lumacaftor 100 mg/ivacaftor
125 mg) Q12 hours PO12
hours PO

$259,588.80

Source: Kalydeco Tablets Label-FDA 2012; Vertex-lumacaftor/ivacaftor package insert 2016; Micromedex solutions 2015# and 2016*
Red book 24-26, WAC: Whole sale acquisition cost ; Q: every; PO: by mouth

EPIDEMIOLOGY

Prevalence
According to 2013 CF Foundation Patient Registry Annual Report, more than 30,000
Americans, 3,000 Canadians, and 20,000 Europeans (more than 70,000 worldwide) are
living with CF. 1, 3 Although the disease affects all races and ethnic groups, it occurs most
commonly in Caucasian individuals with Northern European ancestry than in African
Americans, Native Americans and Asian Americans. In the United States (US), the
prevalence of CF is as follows:


Caucasians of Northern European origin: 1 case per 3,200-3,500 population



Hispanics: 1 case per 9,200-9,500 population



African Americans: 1 case per 15,000-17,000 population



Asian Americans: 1 case per 31,000 population. 27

About 1 in every 20 Americans is an unaffected carrier of an abnormal CF gene. This
accounts to around 12 million CF carriers who are unaware of it. 1 According to 2015 CF
Foundation Patient Registry Annual Report, more than half of the CF population was 18
years or older (Refer Figure 5). 21 CF prevalence was estimated at 28,983 cases in the
2015 Patient Registry Report.
Although there are more than 1,700 known mutations causing CF, only
242 CFTR mutations have been confirmed so far. 28 The prevalence of the gene
mutations varies with geographic location and are presented in Table 4. Most common
mutations were taken from the CF patient registries from different regions and mutations
occurring in more than one percent of patients were included for all regions except
Canada, as it listed only the five most common mutations, all of which occur on one or
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Figure 5: Age distribution and prevalence of cystic fibrosis in 2015

Source: Cystic Fibrosis Foundation Patient Registry, 2015 21

21

Table 4: Most commonly occurring mutations in selected regions
Mutations
621+1G→T
1717-1G→A
2789+5G→A
3120+1G→A
3849+10kbC→T
A455E
F508del
G542X
G551D
N1303K
R117H
R553X
W1282X

United States
X
X
X
X
X
X
X
X
X
X
X
X

Canada
X

X
X
X
X

Europe

Australia
X
X

X
X
X
X

X
X
X
X
X

X

Source: CFTR sciene.com, 2016 28
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both alleles in more than or equal to 2.6 percent of patients. The distribution
of CFTR mutations also vary based on race of the patients. Table 5 depicts the
prevalence of CFTR mutations based on ethnicity.

Incidence
In the US, CF occurs at a rate of 1 in 3,400 births. Approximately 1,000 new cases of CF
are diagnosed each year and more than 75% individuals are diagnosed by two years of
age. According to 2015 CF Foundation Patient Registry Annual Report, 853 new cases
were diagnosed with CF (Refer Figure 6). 21

ECONOMIC BURDEN
Despite a low prevalence, the costs of illness is substantial and the costs vary widely in
different countries. In the US, the mean annual total costs of CF medical care in 1996 was
estimated at $13,300. 29 The costs ranged from $6,200 among patients with mild disease
to $43,300 among patients with severe disease. Of the total costs, 47% were from
hospitalization, 18% were from dornase alfa (DNase or Pulmozyme) prescription
medication, 12% were from clinic visits, and 10% were from outpatient antibiotics. The
annual national costs of medical care for the entire CF population in the US was
estimated at $314 million (1996). However, according to CF Foundation, the average
annual costs of CF care in 1996 was $45,000. 29 A 2006 study reported the average cost
of care for a person with CF living in the US to be around $48,000 which was 20 times
higher than someone without CF. 30
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Table 5: Prevalence of common mutations in cystic fibrosis
Prevalence
1:3500 (United States)
1:3200 (USA Caucasians)
1:15,000 (African Americans)
1:10,000 (Latin Americans)
1:10,500 (Native Americans)

Mutations
F508 del, G542X, G551D, R117H, N1303K
F508 del, G542X, G551D, W1282X
F508 del, A559T, 3120+1G TO A
F508 del, G542X, 406-1 G TO A, 1811 +1.6
Kb A TO G
F508 del, R1162X, L1093P

Source: CFTR sciene.com, 2016 28
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Figure 6: Incidence of Cystic Fibrosis from 1991-2015

Source: Cystic Fibrosis Foundation Patient Registry, 2015 21; NBS: New born screening
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In 2011, the mean annual costs of CF care was about $29,000 per patient, $20,000 for
prescription medications and $22,102 for inpatient hospital stays. Hospital costs have
been shown to account for 75% of the total CF-related services costs (excluding
medications). 31 However, recent study suggested that the annual estimated costs of CF
care in 2011 were $30,000, $57,000, and $215,000 for patients with mild, moderate, and
severe disease, respectively. Costs were highest among children with severe disease of
age group 10-14 years (estimated annual cost of care was $343,900) and decreased in
adults with mild disease with age increasing up to 45 years (estimated annual cost of care
was $15,600 for patients aged 40-44 years). 32

PROBLEM STATEMENT
CF is a rare disease, affecting approximately 0.0089 % of the US population. Even
though the economic burden due to CF is substantial, there is very little data available to
understand the different contributors to the economic burden. Very few studies have
reported burden of illness and CF healthcare resource utilization and majority of those
studies were done in early 2000’s. 29, 30 CF medications and hospitalizations have been
shown to account for higher expenditure among total CF care costs. There are no recent
studies which comprehensively report the economic burden of the disease in terms of
medical resource utilization such as outpatient visits, emergency visits, office visits,
home health, prescription medications and hospital inpatient stays over a time frame.
Hence, burden of illness studies, which provide latest estimates of out-of-pocket (OOP)
and total economic impact of CF are warranted. These studies not only provide in depth
estimates of utilization of various medical services, OOP expenditures and cumulative
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expenditures but also help reflect the economic impact due to CF on the entire US
population by calculating national weighted estimates.
With the introduction of novel CFTR modulator therapies into the market, there is a
paradigm shift in the management of CF. These disease modifying therapies have good
clinical effectiveness including increase in FEV1% values, improvement in revised cystic
fibrosis questionnaire (CFQR) scores, improved body mass index (BMI) and reduction in
pulmonary exacerbation events. These regimens therefore, have the potential to increase
median life expectancy and delay the occurrence of death. However, the annual cost of
ivacaftor is estimated to be over $300,000 and lumacaftor/ivacaftor is estimated to be
around $270,000 as per the dosing regimens. Ivacaftor targets G551D CFTR mutation
whose prevalence is just around 4% in total CF population whereas lumacaftor/ivacaftor
targets F508del mutation whose prevalence is nearly around 90% of total CF population
specifically around 45% with respect to homozygous F508 del mutation. Hence, the
market as well as coverage for lumacaftor/ivacaftor is more than that for ivacaftor alone
as a monotherapy. Ivacaftor was initially approved in 2012 and has been shown to be cost
effective based on published literature 33,
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whereas, lumacaftor/ivacaftor approved in

2015 was rejected by Health Technology Assessments like National Institute for Health
and Care Excellence (NICE) of United Kingdom (UK) and National Centre for
Pharmacoeconomics (NCPE) of Ireland, stating poor cost effectiveness and significant
budget impact with an associated opportunity cost. 35, 36 Little is known if
lumacaftor/ivacaftor is affordable and cost effective in the US healthcare system given
the lack of published literature supporting its cost effectiveness or affordability in the US.
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Given its high costs, there is a need to evaluate the overall value of lumacaftor/ivacaftor
in CF management.

CONCEPTUAL FRAMEWORK
The study has two parts. The first part of the study involved estimating the economic
burden on CF patients using a retrospective cross-sectional cohort study stratified into
two different age groups. This study utilized longitudinal data from 2010-2014 obtained
from Medical Expenditure Panel Survey (MEPS), which collects data from a sample of
families drawn from a nationally representative sub sample of households who participate
in National Health Interview Survey. Patient ID’s with ICD-9-CM diagnosis code of
277.00 for principal diagnosis of CF (2010-2014) were included in the analyses. Full year
consolidated files along with appendix and individual medical events including outpatient
visit, office visit, emergency visit, inpatient stays, home health and prescription
medication files were analyzed to determine patient demographics, clinical characteristics
such as comorbidities and resource utilization related to the above-mentioned events in
different settings. All the analyses were conducted using Statistical Analysis System 9.4
(SAS Institute; Cary, NC). An a priori significance was set at p ≤0.05 was used for all
statistical tests.
The second part of the study involved pharmacoeconomic evaluations including a cost
effectiveness analysis (CEA) to compare the incremental cost effectiveness ratio of
lumacaftor/ivacaftor with placebo and a budget impact analysis (BIA) to estimate the
total budget impact, cost per member per month (PMPM) and cost per treated member
per month (PTMPM) in comparison to an existing standard therapy for CF.
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STUDY HYPOTHESES
The hypothesis for the first part of the study is that the economic burden of illness due to
CF is substantial and prescription medications account for the highest expenditure. The
hypothesis for the second part of the study is that the lumacaftor/ivacaftor has poor cost
effectiveness and high budget impact based on the rejection of the drug by other Health
Technology Assessments.

STUDY OBJECTIVES AND RESEARCH QUESTIONS
The study involved two parts with specific research questions under each part.

Part 1: Burden of illness in cystic fibrosis
To estimate the burden of illness of cystic fibrosis using 2010-2014 MEPS data.
Research questions
1) To describe the demographics, clinical characteristics and resource utilization of CF
patients.
2) To estimate the incremental cost burden of CF group compared to a non-CF group.

Part 2: Pharmacoeconomic evaluation of lumacaftor/ivacaftor
To conduct a pharmacoeconomic evaluation of lumacaftor/ivacaftor in the treatment of
CF.
Research questions
1) To conduct cost effectiveness analysis of lumacaftor/ivacaftor to understand the
overall effectiveness of the drug compared to its costs.
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2) To conduct a budget impact analysis to understand the potential financial impact of
introducing a new drug in a health plan. Both analyses were conducted from a payer
perspective

STUDY SIGNIFICANCE
As stated earlier, CF poses a significant economic burden on patients and the demand for
novel CFTR modulator therapies is increasing due to enhanced benefits and improved
median life expectancy. In the past, very few studies have reported economic burden and
none of them utilized public databases to comprehensively address a wide range of
medical events which influence the cost burden on individuals. Lumacaftor/ivacaftor is a
latest drug approved by US FDA in 2015. Although the drug was rejected by Health
Technology Agencies of a few countries, little is known about its true cost effectiveness
value in the US.
The present study will not only estimate the total cost burden incurred by CF patients due
to healthcare resource utilization of various medical services but it will compare the
differences in costs across medical services used by patients. The study also aims to
estimate the incremental cost burden in CF group compared to a control group. Detailed
understanding of resource utilization pattern along with common comorbidities reported
by patients will help healthcare providers to have a better picture of population at risk or
disease severity groups. Timely management of the disease based on utilization pattern
can help delay disease progression and improve quality of life in CF patients.
To our knowledge, the present study is one of the first studies evaluating the cost
effectiveness of lumacaftor/ivacaftor and the findings are expected to help payers in their
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decision-making process. If this drug is proved to be cost-effective and if it falls under
US national threshold, insurance companies should implement programs to ensure patient
access to these medications as the drug is only covered under Medicare Part D with a
copay range of $6,014 - $24,057. 37
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CHAPTER TWO: LITERATURE REVIEW

CF is a chronic, progressive, genetic disease which is difficult to treat. With the
introduction of novel CFTR modulator therapies, there has been a shift in the
management of CF resulting in delayed disease progression, increased median life
expectancy and improved quality of life. A literature review was conducted to provide
existing evidence to the two major objectives of the study.

PART 1: BURDEN OF ILLNESS IN CYSTIC FIBROSIS
The newly approved CFTR modulator therapies are very expensive and they have a
significant economic burden on CF patients. Hence, there is a need to understand the
economic burden of illness due to CF. The goal was to conduct a systematic literature
review to estimate the total economic burden of illness, healthcare resource utilization
costs and to identify gaps in existing literature.

Methods
Search strategy
A systematic literature search was conducted in peer-reviewed journals using the
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines (Refer Figure 7). 38 The search included all the studies assessing cost of care,
cost of illness, burden of illness, health resource utilization costs in databases such as
PubMed and SCOPUS until February 2017.
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Screening

Identification

Figure 7: Schematic presentation of methodology used in literature review

Records identified through
database searching (PUBMED,
SCOPUS)
(n=309)

Duplicate records
(n=0)

Eligibility

Records screened
(n=309)

Articles assessed for
eligibility
(n=37)

Records not relevant
(n=272)

Articles excluded, with
reasons
(n=19)

Included

Exclusion Criteria
Studies included in
qualitative synthesis
(n=18)
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Non-English: 12
Case report: 1
Erratum: 1
User’s guide: 1
Reviews: 4

Key terms
Cystic fibrosis, database analysis, retrospective database analysis, secondary database
analysis, databases analyses, medical expenditure panel survey, MEPS, healthcare cost
and utilization project, HCUP, patient registry, electronic medical records, EMR,
pharmacy claims data, insurance claims data, administrative claims data, cost of care,
burden of illness, resource utilization, cost of healthcare, cost of illness.
Final search syntax
(“Cystic Fibrosis” [mesh] OR “Cystic Fibrosis” [tiab] OR “Cystic Fibrosis” [ot]) AND
("Database analysis"[tiab] OR "Database analysis"[ot] OR "Database analyses"[tiab] OR
"Database analyses"[ot] OR “medical expenditure panel survey” [tiab] OR “medical
expenditure panel survey”[ot] OR “MEPS” [tiab] OR “MEPS” [ot] OR “healthcare cost
and utilization project” [tiab] OR “healthcare cost and utilization project” [ot] OR
“HCUP” [tiab] OR “HCUP” [ot] OR “National inpatient sample”[tiab] OR “National
inpatient sample”[ot] OR “NIS”[tiab] OR “NIS”[ot] OR “patient registry” [tiab] OR
“patient registry” [ot] OR “electronic medical records ” [tiab] OR “electronic medical
records” [ot] OR “EMR” [tiab] OR “EMR” [ot] OR “pharmacy claims data” [tiab] OR
“pharmacy claims data” [ot] OR “insurance claims data” [tiab] OR “insurance claims
data” [ot] OR “administrative claims data” [tiab] OR “administrative claims data” [ot]OR
“burden of illness” [tiab] OR “burden of illness” [ot] OR “cost of illness” [tiab] OR “cost
of illness” [ot] OR “cost of care” [tiab] OR “cost of care” [ot] OR “resource utlization”
[tiab] OR “resource utilization” [ot] OR “cost of healthcare” [tiab] OR “cost of
healthcare” [ot])
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Inclusion/Exclusion criteria
Journal articles were included if they evaluated burden of illness, cost of care or CF
healthcare resource utilization costs. Reviews, commentaries, editorials and other reports
were excluded. Further the search was limited to studies in English language.
Data extraction
The following variables were extracted from the identified studies: year in which the
study was conducted, author, type of setting in which the study was conducted or the
source of data, patient demographics such as population size, mean age, Gender
distribution, inclusion/exclusion criteria of study population, factors assessed in the study
like inpatient stays, hospitalization costs, total medical costs, prescription medication
costs and important findings from the study.

Results
Of the 309 articles screened, 272 were identified as not relevant and the remaining 37
articles were assessed for eligibility based on inclusion/exclusion criteria. Further 19
articles were excluded and 18 articles were included in the review for qualitative
synthesis. Of the 18 articles, 9 (50%) were conducted in the US, 8 (44.4%) were
conducted in Europe and 1 (5.5%) in Australia. The studies utilized a variety of methods
with 10 (55.5%) studies using retrospective database analysis, 3 (16.6%) studies using
cross sectional analysis of questionnaires and 5 (27.7%) studies using prospective design
were conducted in medical care centers. Most commonly used databases were CF Patient
Registry, administrative, medical claims followed by hospital billing and medical
records. None of the studies were conducted utilizing publicly available databases like
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MEPS. Studies assessed the association between costs and health related quality of life
(HRQoL) in CF, economic burden due to Pseudomonas infection, costs in patients with
lung impairment, expenditures in privately insured patients and costs in pediatric patients.
Factors assessed in the studies were patient demographics, costs for office visits,
hospitalization visits, ER visits, inpatient hospitalizations, prescription medications, total
medical costs, hospitalization length, and time to next hospitalization, cost of informal
care, productivity losses, mortality demographics, complications and costs due to
pulmonary exacerbations. Though costs due to various medical events like office visits,
outpatient visits, emergency visits, home health, inpatient stays and prescription
medications were studied, all of them together were not addressed as a single study. The
findings from the studies suggested that there is an increase in rate of hospitalizations
over the years. Prevalence of comorbid conditions like acute kidney injury and chronic
liver disease have also increased. Patients with prior lung transplantation account for
more hospitalizations. A study conducted by Kopp et al., assessed the impact of
geographic location on hospitalization in CF patients and found that the West region was
associated with risk of longer hospital stays, specifically due to the use of dornase alfa
drug. 39 Old age and history of bronchopulmonary aspergillosis in the Northeast, use of
chronic macrolide drugs in the South and Candida albicans infection or Pseudomonas
aeruginosa in the Midwest were also associated with increased hospitalization length.
Risk for subsequent hospitalizations was significantly less in the northeast compared to
other regions. Another study conducted by Wertz et al., evaluated economic impact of
tobramycin and reported that the total and per member per month costs decreased in
tobramycin inhalation solution users. 40 In 1996, annual cost of CF-related medical care

36

averaged $13,300 with a range of $6,200 among patients with mild disease to $43,300
among patients with severe disease. Of total costs, 47% were from hospitalization, 18%
were from DNase (Pulmozyme), 12% were from clinic visits, and 10% were from
outpatient antibiotics whereas the national estimate of the annual cost of CF-related
medical care in the United States was $314 million per year in 1996. 29 A study
conducted by Ouyang et al., reported annual medical care expenditure for a person with
CF to be $48,098 in 2006, which was 22 times higher than for a person without CF and
outpatient medication costs were the highest cost drivers. 30 Analysis of an administrative
claims data by O'Sullivan et al., reported total annual CF care costs in patients with
pseudomonas aeruginosa infection to be $29,000 and prescription medication cost to be
$20,000 in 2006. 31 Another study conducted using claims data from 2005-2008
estimated the annual per-patient expenditures after a Pseudomonas aeruginosa infection
to increase to $51,821 from a pre-infection annual per-patient medical expenditure of
$33,305. 41 Summary of results is presented in Table 6.
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Table 6: Summary of burden of illness in cystic fibrosis
Study year

Data source

Inclusion

Chatterjee K
et al. 42 2016

2003-2013, NIS
data of HCUP

Exclusion criteria
CF patients with ICD-9CM code 277.00 -277.09
were included

Kopp BT et
al. 39 2016

2007-2012 CF
Foundation
Patient Registry
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Participants with
information on
state of residence, new
births and deaths during
the study period with at
least 1 year of data prior
to death were included

Patient
population

Factors
evaluated

Study findings

N= 311,651, mean
age: 22.3 yrs, age
≥18 yrs: 63.6%,
age <18 yrs:
36.4%, male:
45.8%, female:
54.2%

Inpatient stays,
co-morbidities
during
hospitalizations,
outcomes and
discharge
disposition

 The annual rate of hospitalizations per 1,000 CF
patients in the US increased from 994 to 1,072
from 2003 to 2013
 In-hospital mortality decreased from 1.9% to 1.2%
from 2003 to 2013
 Patients with prior lung transplantation accounted
for 6.5% of hospitalizations and had a significantly
higher prevalence of AKI

N = 30,896

Impact of
geographic
region on
recovery from
hospitalization,
hospitalization
length, time to
next
hospitalization

 Post hospitalization lung function and nutritional
measures were similar among different regions for
1 year.
 Dornase alfa use in west region, history of allergic
bronchopulmonary aspergillosis and adult age in
the Northeast, chronic macrolide use in the South,
and infection with Candida albicans and
Pseudomonas aeruginosa in the Midwest were
associated with increased hospitalization length.
 Risk of subsequent hospitalization was low in the
Northeast compared with other regions.
 Caucasians in the South had significantly lower
risk of future hospitalization compared with
African Americans

2004-2009
administrative
claims data

Individuals aged 0-64
years with at least two
medical claims for CF
on different service dates
in the study period
between January 1, 2004
and March 31, 2009
were included

N= 832.388 TSI
users (mean age
19 years, 48%
female) and 444
non-users (mean
age 30 years, 54%
female)

Differences in
PMPM costs preindex to postindex in
tobramycin
solution for
inhalation users
and non-users

 Total and CF-related PMPM costs decreased $959
(17%) and $113 (3%) respectively after starting
TSI
 CF-related inpatient PMPM costs decreased by
$1,171 (49%; p=0.01), while CF-related
prescription PMPM costs increased by $992
(p<0.01) among TSI users
 CF-related inpatient PMPM costs decreased by
$381 (38%; p=0.16) for low and $1,425 (50%;
p=0.21) for medium users and decreased by $1,829
(51%; p=0.02) for high users

O’Sullivan
AK. 31 2011

2002-2006
administrative
claims data

Patients with at least one
medical claim of CF
with pulmonary
manifestations who were
at least 6 years of age as
of February, 2011or
older as of the year of
the index
date with at least 12
months of continuous
enrollment following the
index date were included
unless there was
evidence that
disenrollment was due to
death

N= 1,064

Costs for office
visits,
hospitalization
visits, ER visits,
inpatient
hospitalizations,
prescription
medications, total
medical costs
were analyzed

 80% had at least one CF-related office visit,
34% had a CF-related hospital stay and 95%
filled at least one prescription over one year
 Total annual CF-related healthcare costs averaged
$29,000 excluding $20,000 for prescription
medications.
 In the subgroup analysis, there was a trend
towards longer lengths of stay and higher
inpatient costs with fewer numbers of TIS
prescriptions filled

Mlčoch T et
al. 43 2017

2009-2011
medical records
from 39ebul CF
Registry and
invoices to
health insurance
companies

 Patients with original
medical/cost records
were included

N= 242

Medical
procedures,
inpatient care,
cost of drugs and
devices

 Mean total healthcare costs were €14,486 per
patient, majority accounted by medicinal products
and devices (€10,321).
 Medical procedures (€2676) and inpatient care
(€1829) accounted to very small percentage.
 Patient age and lung disease severity were the most
important cost drivers
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Wertz DA et
al. 40 2011

 Children younger than
4 years of age, without
cost data, complete
medical records, died
after lung
transplantation and

died with data
collection period were
excluded

 Average annual total cost of CF care was $24,768
 Outpatient drug costs (53%) and hospitalizations
(32%) represented most of costs
 Drug costs were 48% for pulmonary indications
and 52% for non-pulmonary
 Pulmonary drug costs for children taking dornase
alfa were 54% of their drug costs while
pulmonary drug costs were only 31% for children
not taking dornase alfa
 Significant differences in frequency of inpatient
stays existed for children with pancreatic
insufficiency

1989-2010
hospital billing
and medical
records

CF children enrolled in
Wisconsin newborn
screening trial with
hospital billing and
medical records
available from 1989 to
2010 were included

N= 73 children
with CF

Treatments,
hospitalizations,
and nutritional
and pulmonary
outcomes.

Angelis A et
al. 45 2015

Questionnaires
given to
patients and
caregivers
identified from
CFT Registry

Non-institutionalized CF
patients receiving
outpatient care were
included

N= 74 (39 male
and 35 female),
mean age: 18.3
years,

Demographic
characteristics,
health resource
utilization,
informal care,
productivity
losses and
HRQOL

In 2012, average annual cost for a CF patient was
€48,603, with direct healthcare costs amounting to
42.9%, direct non-healthcare costs accounting to
44.3% and indirect costs attributable to productivity
losses accounting to 12.8%.

Chevreul K
et al. 46 2015

Questionnaires
given to
patients

Patients recruited
on a voluntary basis
through the CF reference
center of
Nantes–Roscoff, the
French CF Society and
the patient association

Adults, N= 82,
Children, N= 158

Sociodemographic
characteristics,
healthcare
consumption and
presence of a
carer.

 The total average annual cost of CF care was
€29,746 per patient
 Total costs were higher in adults than in children
and increased with disease duration
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Levy JF et
al. 44 2016

Vaincre la
Mucoviscidose between
September 2012 and
May 2013 were included

Questionnaires
given to
patients or
caregivers

CF patients who
received outpatient care
with the given
community were
included

Patients: N= 33
(<18 years: N =
17), mean age: 16
years,
Carers: N= 17,
mean age: 34 yrs,

Van Gool K
et al. 48 2013

2003-2005
Cystic Fibrosis
Australian
Registry data

De-identified patient
data from Registry

N= 2,255 (male:
52%), mean age:
15.43 yrs

Colombo C
et al. 49 2013

Prospective
observational
study in
Lombardia
regional
CFRRC, Milan,
Italy

Patients seen during an
outpatient visit or who
were hospitalized
between March and July
2009 were included

Children: N= 55
(male ≤5 yrs: N=
25), mean age: 3
yrs
Adults: N= 106
(male >5 yrs: N=
58, mean age: 17
yrs
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Iskrov GG
et al. 47 2015

Sociodemographic
characteristics,
health resource
utilization,
informal care,
labor
productivity
losses
Clinical
measures,
mortality,
demographics,
complications,
and healthcare
resource use

Direct medical
costs including
hospitalizations,
outpatient
interventions,
drugs, devices,
dietetic products

 Median annual cost of CF in Bulgaria was €
24,152 per patient in 2012
 Median annual costs for children were found to be
significantly higher than those for adults.
 Drugs had biggest monetary impact

 The mean annual healthcare cost for treating CF
was US $15,571 in 2013
 Costs for patients with mild, moderate, and severe
disease were US $10,151, US $25,647, and US
$33,691, respectively
 Lifetime healthcare costs were approximately US
$306,332 (3.5% discount rate)
 Most of costs were accounted by hospital inpatients
(58%), followed by pharmaceuticals (29%), medical
services (10%), complications (2%), and diagnostic
tests (1%)
The mean annual cost of care per patient increased
with age and lung disease severity from €4,164 in
children aged ≤5 years to €30,123 in patients aged >5
years with severe lung disease.

Heimeshoff
M et al. 50
2012

Observational
study at CF
treatment center

Patients admitted to an
inpatient unit at a CF
treatment center during
the first 6 months of
2004 and patients who
visited the center’s CF
outpatient unit during
the entire year were
included

N= 266 (inpatient:
N= 87,
Outpatient: N=
125,
inpatient and
outpatient: N= 54)

Resource
utilization data

Sansgiry SS
et al. 41 2012

MarketScan
claims database

 Cases continuously
enrolled in a managed
care plan for 12
months before and
after the index date
were included

N= 358 (female:
48%), mean age:
20.1 yrs,

Healthcare
utilization,
medical and
pharmacy costs

42

 Individuals with a
prior PA infection,
enrolled in capitated
plans, without
prescription
medication coverage
or not
continuously enrolled
with complete medical
coverage were
excluded

 Mean total cost per patient per year was €41,468 in
2004
 Direct medical costs accounted for more than 90%
of total costs and averaged €38,869 (€3,876 to
€88,096), whereas direct non-medical costs were
minimal
 Indirect costs amounted to €2,491 (6% of total
costs)
 Important cost driving factors were outpatient
pharmacy, disease severity
Average annual cost per patient following initial
Pseudomonas aeruginosa infection increased by an
estimated $18,516 of $3,113 was accounted by
outpatient costs, $10,123 was accounted by inpatient
costs and $4,943 was accounted by pharmacy costs

Dewitt EM
et al. 51 2012

RCT, study case
report forms,
Medicare
physician fee
schedule, the
NIS and the
Red Book

 Participants aged 5
years or older with a
confirmed diagnosis
of CF and mild
impairment in lung
function with FEV1%
predicted of 75% with
clinical stability for 4
weeks before
screening were
included
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 Exclusion criteria
included abnormal
renal or liver
function, history of
liver or lung
transplant,
Burkholderia cepia
infection, change in
medications within 28
days of screening, use
of inhaled hypertonic
saline within 2 weeks
of screening, and use
of oral corticosteroids
exceeding 10 mg
once daily or 20 mg
every other day

N= 352, mean
age: 14.6 yrs

Medications,
outpatient,
emergency visits,
hospital
admissions, tests,
procedures and
home nursing

 Mean total costs (excluding denufosol) were
$39,673 (SD $26,842) in 2007 of which 85%
were attributable to medications
 Female sex and P. aeruginosa infection were
associated with higher costs

Ouyang L et
al. 30 2009

2004-2006
insurance
claims data

44
Huot L et al.
52
2008

Questionnaire
given to
patients
enrolled in a CF
reference center

 Subjects enrolled in
fee for-service
plans, having a CF
diagnosis from
either inpatient or
outpatient visit claims
in each year between
2004-2006 with only
one year or multiple
years of data available
if they had at least one
CF diagnosis recorded
in those claims were
included
 Individuals without
complete insurance
coverage for 12
months in each year,
enrolled in capitated
plans, without
prescription
medication coverage in
their insurance plans
were excluded
Patients covered by local
French NHI system in
2000 and 2003 who
filled out a questionnaire
in 2000 and existing
patients in the NHI
claims database in 2003
were included
Newborns with the
illness detected at birth
in 2003 and patients who
had a lung transplant
were excluded

N= 65 in 2000,
N= 64 in 2003

Medical care
expenditures,
including both
insurance
reimbursements
and patient OOP
expenses

 The annual medical care expenditure for a person
with actively managed CF averaged $48,098 in
2006, which was 22 times higher than for a person
without CF
 Outpatient medication costs were the highest cost
drivers

Direct medical
costs in 2000 and
2003

 Average cost of care was €16474/patient/year in
2000 and €22,725 in 2003
 Hospital care increased from 15% of the total cost
in 2000 to 22% in 2003
 Medications accounted for 45% of the total cost
for the two periods, with an average cost of
€7,229/patient/year in 2000 and €10,336 in 2003
 Home intravenous antibiotic therapy accounted for
20% of the total cost for the two periods

Baumann U
et al. 53 2003

Lieu TA ey
al. 29 1999

Databases of
hospital
administration,
diagnostic
departments,
clinical
database of CF
unit and patient
records.
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Computerized
cost database
(medical
records) and
CFF annual
survey

 Pediatric CF
population from
Hanover Medical
School over a period
of 1 year regularly
attending the CF center
were included
 Population with
additional diseases
unrelated to CF or with
a shared care from
other CF-centers were
excluded
Those who had
continuous health plan
membership with Kaiser
Permanente Medical
Care Plan via
commercial insurance
during 1996.

N= 138 (male:
54%)

Clinical
parameters and
healthcare
utilization

 Total annual expenditure per patient amounted to
€23,989 between 1996-1997 with home drug
treatment representing the most important single
cost factor (47% of total costs).
 Costs increased with age and doubled in the first
18 years and they correlated with P. aeruginosa
airway colonization status and FEV1.
 Costs of patients with chronic P. aeruginosa
infection were more than three times higher than
for uninfected patients.

N= 136 (male:
52%, whites:
93%), age: 9
months to 56 yrs
(mean: 16.6 yrs,
median: 13 yrs),
age ≥18 years:
N=44, all had
graduated from
high school or had
attended college
and 50% were
employed

Demographics,
severity of
illness, and other
clinical
information

 Annual cost of medical care in 1996 averaged
$13,300 ranging from $6,200 among patients with
mild disease to $43,300 among patients with
severe disease
 Of total costs, 47% were from hospitalization, 18%
were from Dnase (Pulmozyme®), 12% were from
clinic visits, and 10% were from outpatient
antibiotics
 Costs of medical care for the entire population of
CF patients in the US were estimated to be $314
million per year in 1996

NIS: National Inpatient Sample; HCUP: HealthCare Cost and Utilization Project; N: sample size; yrs: years; AKI: acute kidney
injury; TSI/TIS: tobramycin solution for inhalation; PMPM: per member per month; ER: emergency; CFT: cystic fibrosis trust;
HRQOL: health related quality of life; PA: Pseudomonas aeruginosa; RCT: randomized clinical trial; FEV1% predicted: percent
predicted FEV1; FEV1: forced expiratory volume in one second; NHI: national health insurance; CFF: Cystic Fibrosis Foundation;
CFRRC: cystic fibrosis reference center; OOP: out-of-pocket

PART 2: PHARMACOECONOMIC EVALUATIONS IN CYSTIC
FIBROSIS
High medication acquisition costs associated with novel CFTR modulator therapies have
warranted the need for cost effectiveness analyses of these drugs. However, it is also
necessary to understand the economic impact of the disease and the economic evaluations
of existing drugs in CF treatment to assess the need for novel therapies. The goal was to
conduct a systematic review of pharmacoeconomic evaluation studies in CF to assess the
impact of disease on patients and to identify existing literature on costs effectiveness of
lumacaftor/ivacaftor.

Methods
Search strategy
A systematic literature search was conducted in peer-reviewed journals using the
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines (Refer Figure 8). 38 The search included all the economic evaluation studies
assessing cost of illness, cost effectiveness, budget impact, cost utility, cost benefit,
decision analysis of existing and novel therapies using databases such as PubMed and
SCOPUS until February 2017.
Key terms
Cystic fibrosis, ivacaftor, Kalydeco, lumacaftor/ivacaftor, Orkambi, pharmacoeconomic
evaluation, pharmacoeconomic analysis, economic evaluation, costs, cost effectiveness
analysis, CEA, cost of illness COI, cost minimization analysis, CMA, cost benefit

46

Identification

Figure 8: Schematic presentation of methodology used in literature review

Records identified through
database searching (PUBMED,
SCOPUS
(n=451)

Included

Eligibility

Screening

Duplicate records
(n=38)

Records screened
(n=413)

Records not relevant
(n=352)

Articles assessed for
eligibility
(n=61)

Articles excluded, with
reasons
(n=47)

Studies included in
qualitative synthesis
(n=14)
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Exclusion Criteria
Reviews: 21
Non-English: 15
Case studies, RCT: 3
Other reports, updates,
monographs, editorials: 8

analysis, CBA, budget impact analysis BIA, cost utility analysis, CUI, decision analysis,
decision tree, Markov model, simulations model.
Final search syntax
(“Cystic Fibrosis” [mesh] OR “Cystic Fibrosis” [tiab] OR “Cystic Fibrosis” [ot] OR
“Ivacaftor” [tiab] OR “Ivacaftor” [ot] OR “Kalydeco“ [tiab] OR “Kalydeco” [ot] OR
“Orkambi” [tiab] OR “Orkambi” [ot] OR “Lumacaftor/Ivacaftor” [tiab] OR “Lumacaftor/
Ivacaftor” [ot]) AND (“Economics, Pharmaceutical”[Mesh] OR “pharmaceutical
economics”[tiab] OR “pharmaceutical economics”[ot] OR “pharmacoeconomics”[tiab]
OR “pharmacoeconomics”[ot] OR “pharmacoeconomic”[tiab] OR
“pharmacoeconomic”[ot] OR“Economic evaluation”[tiab] OR “Economic
evaluation”[ot] OR “costs” [tiab] OR “costs” [ot] OR “Cost effectiveness analysis” [tiab]
OR “Cost effectiveness analysis” [ot] OR “CEA” [tiab] OR “CEA ” [ot] OR “Cost of
illness”[tiab] OR “Cost of illness”[ot] OR “COI” [tiab] OR “COI” [ot] OR “Cost
minimization analysis” [tiab] OR “Cost minimization analysis” [ot] OR “CMA” [tiab]
OR “CMA” [ot] OR “Cost benefit analysis” [tiab] OR “Cost benefit analysis” [ot] OR
“CBA” [tiab] OR “CBA” [ot] OR “Budget impact analysis” [tiab] OR “Budget impact
analysis” [ot] OR “BIA” [tiab] OR “BIA” [ot] OR “Cost utility analysis” [tiab] OR “Cost
utility analysis” [ot] OR “CUI” [tiab] OR “CUI” [ot] OR “Decision analysis” [tiab] OR
“Decision analysis” [ot] OR “Decision tree” [tiab] OR “Decision tree” [ot] OR “Markov
model” [tiab] OR “Markov model” [ot] OR “Simulations model” [tiab] OR “Simulations
model” [ot])
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Inclusion/Exclusion criteria
Journal articles were included if they evaluated cost of illness or cost effectiveness,
budget impact, cost utility, cost benefit, decision analysis of therapies used in CF
treatment. Reviews, commentaries, editorials and other clinical trials reports were
excluded. Further the search was limited to studies published in English and after January
1st, 2000.
Data extraction
The following variables were extracted from the identified studies: year in which the
study was conducted, type of economic evaluation, model used, perspective of the study,
time horizon considered for evaluation, source of data for model inputs, comparators used
in the evaluation, outcomes of the study, type of sensitivity analysis, year in which costs
were calculated (price year), discount rate used, results including the ICERs, and
sponsors of the study, if any.

Results
Of the total 451 articles identified using the search syntax, 38 duplicate records were
eliminated and 352 articles were identified to be irrelevant. 61 articles were assessed for
eligibility based on inclusion/exclusion criteria. 47 articles were excluded with reasons
and 14 articles were included for qualitative synthesis. Of the 14 articles included, 5
(35.7%) studies were conducted in the US, 7 (50%) in Europe and 2 (14.2%) in Australia.
5 studies conducted in the US included 2 (40%) cost effectiveness analyses, 2 (40%) cost
benefit analyses and 1 (20%) budget impact model. Cost effectiveness analyses and
budget impact models were conducted from a US third party payer perspective.
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Medications evaluated for overall costs effectiveness and affordability included ivacaftor,
inhaled aztreonam lysine and tobramycin inhalation solution whereas cost benefit
analyses were conducted for diagnostic tests including carrier screening and genetic tests.
The outcomes assessed in a cost effectiveness analyses included cost per QALY and
incremental life time costs. Total increase in the budget and per member per month cost
were the primary outcomes of the budget impact model whereas cost benefit analysis
assessed net benefit due to screening tests and average annual, lifetime direct medical
costs per CF patient avoided. All the five economic evaluations used Markov models and
involved one way, probabilistic sensitivity analysis. All costs were discounted at rate of
3%. A study conducted by Dilokthornsakul et al., 34 to evaluate the cost effectiveness of
ivacaftor reported that ivacaftor was associated with 18.25 additional life-years and 15.03
additional quality-adjusted life-years. Ivacaftor has also been shown to improve
morbidity and mortality similar to that of non-CF patients. A comparative CEA of
aztreonam vs. tobramycin reported aztreonam lysine inhalation to be associated with an
average cost saving of $41,947 per patient over 3 years along with greater qualityadjusted life-years and total life-years in 2013-2014. 54 A cost benefit analysis suggested
that the cumulative net saving of a genetic test for all carrier-couples was $33.3 billion in
2006. 55
Other studies conducted outside the US included 3 cost effectiveness analyses of dry
powder antibiotics, ivacaftor and carrier screening, 2 cost of illness studies, 3 cost
analyses and 1 cost consequence analysis. Most of the studies were sponsored by
pharmaceutical companies or a health research organization and the inputs for cost
effectiveness analyses were provided by the manufacturing companies. There was no
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evidence of a CEA conducted for lumacaftor/ivacaftor in the literature with in the United
States as well as outside the country although the drug was approved in 2015. The
economic evaluations included antibiotics, screening techniques and overall cost of
illness. There was only a single study which was identified to evaluate the cost
effectiveness of a novel CFTR therapy called ivacaftor. The literature review clearly
demonstrated the need for establishing the overall cost effectiveness as well as
affordability of the drug lumacaftor/ivacaftor in the United States as well as outside the
country. Summary of results presented in Table 7.
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Table 7: Summary of pharmacoeconomic evaluations in cystic fibrosis
Study
Year

Type of
economic
evaluation

Study perspective

Treatment

Time horizon

Comparator

Model

Data source

Outcomes

Sensitivity
analysis

Findings

Sponsor

Price year
Dilokthor
nsakul P
et al. 33,34
2016

 Cost
effectiveness
analysis and
budget
impact
model

 US Payer
 Life time
 Published
literature

 Ivacaftor plus
usual care
 Usual care
alone

Cost/QALY,
incremental
life time cost,
PMPM
budget
impact

 Markov
model

52

Schechter  Cost
MS et al.
effectiveness
54
2015
analysis
 Markov
model

Discount rate
 One way,
probabilistic
sensitivity
analysis
 2013
 3%

 US Payer
 3 years
 Comparator trial
data including
clinical outcomes,
QOL. Costs from
published
literature and
proprietary
databases.

 Inhaled
aztreonam
lysine
 Inhaled
tobramycin

Over all costs
for two
treatments,
QALY, total
life years

 Extensive
scenario and
probabilistic
sensitivity
analysis
 2013-2014
 3%

 Incremental lifetime cost
was $3,374, 584
 The budget impact was
$0.087 PMPM
 Ivacaftor increased lifeyears and QALY’s in CF
patients with the G551D
mutation and moved
morbidity and mortality
closer to that of non-CF
population
Use of aztreonam lysine
for inhalation was
associated with an average
cost saving of $41,947 per
patient over 3 years as
well as greater QALY and
total life-years.

None

Abacus
Internatio
nal,
Gilead
Sciences

Whiting
P et al. 33
2014

Tappende
n P et al.
56
2014

 Cost
effectiveness
analysis

 NHS perspective

 Markov
model

 Inputs from
manufacturers
model with
modifications
specific to UK

 Cost
effectiveness
analysis

 NHS and PSS

 State
transition
model

 Patient level and
aggregate data
from RCT’s and
literature.
Resource use and
costs associated
with drug
acquisition,
management of
exacerbations and
reduced
53ebulized
maintenance from
reference sources
and expert
opinion.
 Societal
perspective

53
Heimesh
off M et
al. 50
2012

 Life time

Cost of
illness

 1 year

 1 year
 Direct medical
costs from
outpatient

 Ivacaftor plus
standard care

ICER, cost /
QALY
gained.

 Standard care

 Probabilistic
sensitivity
analysis
 2010
 3.5 %

 Colistimethate
sodium DPI,
tobramycin
DPI

ICER, cost /
QALY
gained.

 Nebulised
tobramycin

 Simple and
probabilistic
sensitivity
analysis
 2011/2012
 3.5 %

NA

Average total
costs of CF
per patient
and per year

 Monte Carlo
simulation
 2004
 Not reported

 The ICER varied between
£335,000 and £1,274,000
per QALY gained.
 The total additional
lifetime costs for all
eligible CF patients in
England ranged from
£438M to £479M.
 The lifetime cost for
standard care alone was
£72M.
 Colistimethate sodium
DPI produced fewer
QALY’s than nebulized
tobramycin and the ICER
was approximately
£288,600 saved per QALY
lost.
 The ICER for tobramycin
DPI versus nebulized
tobramycin was £124,000
per QALY gained.

Vertex
Pharmac
euticals

 Mean total cost per patient
per year was €41,468
 Direct medical costs
accounted for more than
90% of total costs and
averaged €38,869 (€3,876
to €88,096), whereas
direct non-medical costs
were minimal

None

NIHR
HTA

 Indirect costs amounted to
€2,491 (6% of total costs)
 There was a 90%
probability that annual
costs will be lower than
€37,300

pharmacy, direct
non-medical and
indirect costs
collected from
patients

Norman
R et al. 57
2012

 Cost
effectiveness
analysis
 Decision tree
model

54
Woodwar  Budget
d TC et
impact
al. 58
analysis
2010
 Population
based MS
Excel model

 Healthcare system
perspective

 Carrier
screening

 Life time

 No screening

 Australian DRG
data, screening
costs from Human
Genetics
Society of
Australia CF
carrier screening
position statement,
lifetime costs of
management of a
CF patient
were estimated
using Australian
Registry data of
CF patients
 US MCO
perspective
 4 years
 RCT’s, model
assumptions by
KOL, CFF Patient
Registry Annual
Data, costs from
published

 Tobramycin
inhalation
solution plus
standard care
 Standard care
alone

Effectiveness  Univariate
was
sensitivity
expressed in
analysis
terms of CF
births
 2010
averted,
incremental
 5%
cost per CF
birth

 Screening reduced the
annual incidence of CF
births from 34 to
14/100,000 births
 In initial pregnancies,
costs in the screening arm
exceeded those in the nonscreening arm
 Pre-collected information
reduced the incidence of
CF in subsequent
pregnancies at low
additional costs

Cystic
Fibrosis
Australia
and a
National
Health
and
Medical
Research
Council
Health
Services
Research

 One-way
sensitivity
analysis

 Assuming an increase in
TIS use from 20% to 25%,
the 1-year budget
increased $231,251 or
from $0.049 to $0.053
PMPM
 The net drug budget
increase was $243,919
 Increasing utilization of
TIS, from 20% to 40%
over 4 years resulted in an

Novartis
Pharmac
euticals

Total
increase in
budget,
PMPM
budget

 2008
 Not reported

literature based on
Medicare
reimbursements

TurKaspa I
et al. 59
2010
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Maxwell
S et al. 60
2010

 Cost benefit
analysis

 Perspective of
RGI

 Markov
model

 Life time

 Cost
consequence
analysis
 Decision tree
model

incremental overall budget
increase of $925,002

 PGD test cost

 Administrative
records, specialty
pharmacy bills

 Average
annual and
lifetime direct
medical costs
per CF patient
avoided.

 Public health
sector perspective

 Carrier
screening

 Life time

 No screening

 Probability and
cost estimates for
the analysis from
published
literature, current
prenatal screening
program data,
specialist clinical
input and national
health data.

Cumulated
net saving of
an IVF-PGD
program,

 Not reported
 2006
 Not reported

Total costs
for screening,
net savings
due to no
screening

 One-way
sensitivity
analysis
 2008
 3.5%

 Net savings of IVF-PGD
program would be $2.3
million per patient and a
$2.2 billion for all new CF
patients annually in life
time treatment costs
 A total of 618,714
cumulative years of
patients suffering because
of CF and thousands of
abortions could be
prevented
 Annual cost to provide a
prenatal CF carrierscreening program is
Au$5.32 million, Au$3.35
million and $2.93 million
for one-step, two-step
simultaneous and two-step
sequential screening
respectively
 No screening model
provided a net saving over
a lifetime horizon

Partial
funding
by
Institute
for
Human
Reproduc
tion
Chicago.

None

Davis LB
et al. 55
2010

 Cost benefit
analysis
 Markov
model

 Outpatient
reproductive
health practices
 Life time

 PGD for carrier
couples CF
 Natural
conception
(NC)

 Data from RCT’S
case series, case
control,
observational
studies and
databases

Huot L et
al. 52
2008

Cost of
illness

56

 Perspective of
French national
healthcare
insurance

NA

Net benefit
of giving
birth to a
child as the
present value
of lifetime
earnings
minus
lifetime
medical costs
(Net benefit
in)

 One-way
sensitivity
analysis

Annual total
costs of CF

 Not reported

Horvais
V et al. 61
2006

Cost analysis
of inpatient
and
outpatient
costs

 1 year
 Data were
obtained from
medical records,

 3%

 2003
 Costs were not
discounted

 1 year
 Information on
sociodemographic
data and CF
characteristics
were collected
from the patients’
medical records
 Perspective of the
French healthcare
system.

 2007

NA

Annual total
costs of CF
care

 Not reported
 2000-2001
 Not reported

 For women, younger than
35 years of age, the net
benefit of PGD over NC
was $182,000 ($715,000
vs. $532,000,
respectively).
 For women aged 35 – 40
years, the net benefit of
PGD over NC was
$114,000 ($634,000 vs.
$520,000, respectively).
 For women, older than 40
years, the net benefit of
PGD over NC was
$148,000 ($302,000 vs.
$450,000 respectively).
Average annual cost of
CF was €16,474 per
patient in 2000, and
€22,725 in 2003 (based on
the 2003€ value).

 The total annual cost of
CF care totaled €16,189
per patient
 Outpatient costs accounted
for 88% of the total cost
versus 12% for inpatient
costs
 Medication costs were the
highest with 21% of the

None

Vaincre
la
Mucovis
cidose
associati
on and
the Lilly
Institute
funds for
medicoeconomic
evaluatio
n
French
Cystic
Fibrosis
Associati
on
“Vaincre
la
Mucovis
cidose”
and from

and questionnaires
filled out by the
patients.

Elliott
RA et al.
62
2005

Cost analysis

 UK NHS hospital
trust
 1 year

total cost for home
intravenous antibiotic
treatments and 49% of the
total cost for chronic
medications.

 Home care

Annual cost
of care

 Hospital care

 Not reported
 2002
 Not reported

 Data from clinical
records

57
WeijersPoppelaar
s FA et
al. 63
2005

Cost analysis

 Societal
perspective
 Life time
 Published
literature

 Single-entry
two-step
(SETS)
 Double-entry
two-step
(DETS)

Net costs of
carrier
screening
techniques

 Univariate and
multivariate
sensitivity
analysis
 2002
 4%

Patients who had >60 % of
courses at home over 1
year had a mean cost of
£13,528, compared with
22,609 pounds for patients
who had > 60 % of
courses in the hospital and
a mean cost of £19,927 for
patients who had an equal
mix of home and hospital
care
SETS screening during GP
consultations was the least
expensive (net cost of US
$1,111,354 per year)

the
Program
me
Hospitali
er de
Recherch
e
Clinique
(PHRC
—Health
ministry)
.
School of
Pharmac
y
and
Pharmac
eutical
Sciences,
Universit
y of
Manchest
er
Netherla
nds
Organisat
ion for
Health
Research
and
Develop
ment

QALY: quality adjusted life years; QOL: quality of life; NHS: National Health Service; ICER: incremental cost effectiveness ratio; M:
million; PSS: personal social services; DPI: dry powder for inhalation; NIHR: National Institute for Health Research; HTA: Health
Technology Assessment; NA: not applicable; DRG: diagnosis related group; A$: Australian dollar; MCO: managed-care organization; KOL: key
opinion leaders, CFF: Cystic Fibrosis Foundation; RGI: Reproductive Genetics Institute; IVF: in-vitro fertilization; PGD: pre implantation
genetic diagnosis; GP: general physician

CHAPTER THREE: METHODS

The study comprises of two parts. The objective of Part 1 was to estimate the economic burden
of illness due to healthcare resource utilization in patients with CF. Cumulative and OOP
expenditures due to various medical events were calculated using 2010-2014 MEPS data. The
objective of Part 2 was to evaluate the cost effectiveness and budget impact of
lumacaftor/ivacaftor in the treatment of CF. Economic models were developed using drug costs
taken from the 2015 Red Book, clinical effectiveness from clinical trials, monitoring and adverse
event costs from published literature and physician fee schedule. This chapter includes a
description of data sources and the methodologies for both parts of the study.

PART 1: BURDEN OF ILLNESS IN CYSTIC FIBROSIS
MEPS is a publicly-available healthcare database which is collected and maintained by the
Agency for Healthcare Research and Quality (AHRQ). The national data is a set of large-scale
surveys of families and individuals, their medical providers (doctors, hospitals, pharmacies) and
employers. MEPS collects data on specific health services such as frequency of healthcare
resource use, cost of services, mode of payment (public/private insurance) as well as data on the
cost, scope and extent of health insurance availability. 64
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Components of MEPS data
Two major components of MEPS include the household and the insurance component. In the
household component (HC), data is collected from a sample of families and individuals drawn
from a nationally representative subsample of households who participated in the previous year’s
National Health Interview Survey, which is conducted by the National Center for Health
Statistics. Information collected in the HC include demographic characteristics, health
conditions, health status, medical services use, charges and source of payments, health insurance
coverage, income, and employment.
The Insurance component (IC) collects data on health insurance plans offered by a sample of
private and public-sector employers to their employees. It consists of information on number and
types of private insurance plans offered (if any), premiums, contributions by employers and
employees, eligibility requirements, benefits associated with these plans and employer
characteristics.
MEPS also includes a medical provider component (MPC) which covers hospitals, physicians,
home healthcare providers and pharmacies identified by HC respondents. This component is
used to supplement or replace information received from the HC respondents, if needed. 65

Data collection
MEPS collects data using an overlapping panel design. A new panel of households is selected
every year and data for each panel is collected for two calendar years in five rounds of interviews
conducted over two years. This design provides continuous and current estimates of healthcare
expenditures at both the person and household level for two panels for each calendar years. The
timing and relationship between panels, rounds, and calendar years are depicted in Figure 9. 65
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Figure 9: MEPS panel design: Data reference periods

Source: MEPS, panel design; 66 N: number of persons with positive person weight on the file;
For example, panels 18 and 19 consist of five rounds of interviews with rounds 3-5 (of panel 18)
and rounds 1-3 (of panel 19) providing data for 2014. Data for the year 2015 consists of data
collected from rounds 3-5 (of panel 19) and rounds 1-3 (of panel 20)
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Household component of MEPS
Data files in HC include full year and medical events like prescribed medicines, dental visits,
hospital inpatient stays, emergency room visits, outpatient visits, office-based medical provider
visits, home health, appendix to MEPS events and other medical expenses files.

Description of HC data files
Full year consolidated file
Full year consolidated file consists of demographics, patient identifiers, health status, variables
related to disability days, access to care, employment, quality of care, patient satisfaction, health
insurance and use variables, income variables and expenditure variables. 67
Medical conditions file
This file provides information on the household-reported medical conditions based on
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9) and
clinical classification codes. 68
Prescribed medicines file
Each record in the prescribed medicines file represents one prescribed medicine purchased or
obtained by the household respondent during a given calendar year. Each prescription record
includes an identifier for a unique prescribed medicine, characteristics associated with the event
(for example, National Drug Code [NDC], medicine name etc.), conditions associated with the
medicine, the date on which the person first used the medicine, total expenditure and sources of
payment, types of pharmacies that filled the household’s prescriptions and a full year personlevel weight. 69

61

Hospital inpatient stays file
Each record in the hospital inpatient stays file represents one inpatient hospital stay reported by a
household during a given calendar year. The data in the file includes the date of the hospital
inpatient stay, reason for the stay, types of services received, conditions and procedures
associated with the hospital inpatient stay, medicines prescribed and imputed expenditure data. 70
Emergency room visits file
Each record in the emergency room visits file represents one emergency room visit reported
during a given calendar year. The data includes the date of the visit, types of care and services
received, types of medicine prescribed during the visit, condition codes, expenditures and
sources of payment associated with the visit. 71
Outpatient visits file
Each record in the outpatient visits file represents one outpatient visit reported during a given
calendar year. The data includes the date of visit, whether a doctor was seen, type of care
received, type of services provided, expenditures and sources of payment. 72
Office-based medical provider visits file
Each record in the office-based medical provider visits file represents one office-based medical
provider visit reported during a given calendar year. As the data includes the date of visit, time
spent with the provider, types of treatment and services received, types of medicine prescribed,
condition codes, expenditures and sources of payment associated with the visit. 73
Home health file
Each record in the home health file represents one home health event reported during a given
calendar year. The data includes the type of provider, type of services received, length of visit,
reason for the visit, expenditures and sources of payment. 74
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Appendix to event files
Appendix consists of files which are used to link medical condition file and prescribed medicines
file with other event files and. 75

Description of study variables
Dependent variables

Cumulative and OOP expenditure
Cumulative expenditure was defined as the sum of direct payment for care provided during the
year, including OOP and payments by private insurance, Medicaid, Medicare, and other sources.
Payments for over-the-counter drugs were not collected in MEPS. Indirect payments not related
to specific medical events such as Medicaid Disproportionate Share and Medicare Direct
Medical Education subsidies, were also not included. Each year, cumulative and OOP
expenditure information was captured for different medical events like home health, office visits,
outpatient visits, emergency visits, inpatient stays and prescription medications. In addition,
cumulative and OOP expenditures for doctor and for facility were captured separately for
inpatient stays, outpatient and emergency visits.
Independent variables
Age
Age was included as a continuous variable and calculated as the difference in years between the
date of birth and the date of the interview. For the present study, age was categorized into two
groups- ≥18 years (adults) and <18 years (children), to study the differences in demographics,
clinical characteristics and expenditures.
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Gender
Gender was categorized as male and female.
Race
Race was represented as a categorical variable with five categories - White, Black, Hispanic,
Asian and Other.
Household income
Household income was defined as the family’s total income in US dollars and was included as a
continuous variable.
Marital status
Respondents reported their current marital status during the interview. The original variable
consisted of six categories - married, widowed, divorced, separated, never married and under 16
years, which was collapsed into three categories for the study - married, not married and under
16 years. The ‘not married’ category comprised of never married, widowed, divorced and
separated.
Insurance coverage
The insurance coverage variable had three different categories - private (insurance provided
through employment, TRICARE), public (Medicaid, Medicare) and uninsured.
Comorbidities
MEPS captured information about comorbid conditions such as high blood pressure, coronary
heart disease, angina, heart attack, stroke, other heart diseases, emphysema, high cholesterol,
cancer, diabetes, arthritis, asthma among adults (age ≥18 years) whereas in children (age <18
years) the only comorbid condition captured was asthma.
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Sample selection
Selection of cases
From the medical conditions file, individuals with CF were identified using the ICD-9-CM code
277.00. Because MEPS uses a panel survey design where an individual could be interviewed for
five rounds over two calendar years, it was possible that an individual might have appeared in
the sample more than once. Thus, unique records which reported using at least one CF-related
medical service were identified, creating the final sample utilized for all the study analyses.
As per the 2015 CF Foundation Patient Registry Report, the prevalence of CF was different in
adults and children. 21 Previous studies have reported higher annual CF care costs in children
than in adults. In addition, differences exist in the number of comorbidities in children and adults
with CF, which may have further impacted the costs and resource utilization in CF care. 31
Hence, cases were stratified into children (age <18 years) and adults (age ≥ 18 years) (Refer
Figure 10).
Selection of controls
From the medical conditions file, those patients without an ICD-9-CM code listed for 277.0 were
identified as a control group and stratified into children (age <18 years) and adults (age ≥18
years) (Refer Figure 11).

Data Analysis
Demographics and clinical characteristics in cases and controls
Descriptive analyses were conducted to describe the demographics and clinical characteristics in
cases and controls followed by an independent sample t-test or a chi-square test depending on the
type of variable to compare significant mean differences between both the groups.
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Figure 10: Criteria for selection of cases
Records in medical conditions file of MEPS data with ICD-9-CM code 277.0
(N=179)

Number of unique records
(N=130)

Number of unique records which reported
usage of at least a single medical service
(N=109)

Adults
(N=78)

Number of unique records reported
without any usage of medical service
(N=21)

Children
(N=31)
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Figure 11: Criteria for selection of controls
Records in medical conditions file of MEPS data with ICD-9-CM code not
equal to 277.00
(N=570,150)

Adults
(N=476,181)

Children
(N=93,969)

Unique records
(N=85,521)

Unique adults
(N=60,871)

Unique children
(N=24,650)
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Resource utilization in cases
Resource utilization among cases was assessed by calculating expenditure for various medical
events like office visits, home health, prescription medications, inpatient stays, outpatient visits
and emergency visits from 2010 to 2014. Weighted and unweighted OOP and cumulative mean
and total direct payments for care provided during the year for all the observations of a medical
event were calculated. OOP expenditure was defined as the expenditure paid directly by an
individual. Cumulative expenditure was defined as expenditure paid by an individual and
payments by private insurance, Medicare, Medicaid and other sources. For office visits, home
health and prescription medications, cost of care was reported as OOP and cumulative
expenditure whereas for other medical events, OOP and cumulative expenditures were further
classified into payment for facility and payment for doctor. For each of the five years, medical
conditions file was linked with appendix file using unique condition ID. The resulting file was
then merged with each event file using unique a medical event ID. Six such files were created for
six types of medical events. Each file was later merged with a full year consolidated file using a
unique person ID. The resulting files represented those observations which had ICD-9-CM code
of 277.0 and records related to a medical event. The observations extracted from 2010-2014 are
presented in Table 8.
For every record, a total cumulative expenditure variable was created for every medical event, by
adding up the expenditure on every occasion of the associated medical event. Similarly, a total
OOP expenditure variable was created by adding the OOP expenditure incurred on every
instance of a medical event. A person-level weight was used to compute national estimates of
expenditures.
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Table 8: Number of observations in each medical event file from 2010-2014
Event

Home health
Inpatient stays
Office-based
medical office visits
Outpatient visits
Emergency room
visits
Prescription
medications

Observations

Total

Unique
observations
2010-2014
16
4
16
11
283
85

2010
7
1
34

2011
0
2
37

2012
0
3
93

2013
2
5
66

2014
7
5
53

4
0

30
3

47
2

9
3

3
7

93
15

22
12

57

67

182

129

119

554
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Resource utilization in controls
For each of the five years, medical conditions file was linked with full year consolidated file
using unique person ID (DUPERSID). The resulting files represented those observations that did
not have CF (patients without an ICD-9-CM code for 277.00) and records related to a medical
event. Similar to cases, total expenditure variable was created for each unique individual in the
control sample.
Incremental cost burden in cases over controls
The incremental cost approach estimates the excess expenditures associated with the disease and
is the difference in expenditures between the cases and the controls. 76-82 The incremental
expenditure methodology captures expenditures solely attributable to a disease, as it adjusts for
differences in variables considered to have an impact on expenditures. 77, 83 Multivariate
modeling is difficult to use for healthcare expenditure data because of its peculiar distribution
which includes restricted range (non-negative observations), excessive zero values and skewness.
84

It is challenging to select an appropriate multivariate model specification to assess the

incremental expenditure associated with a disease. Generalized linear model (GLM) is now
considered efficient to model expenditure data. 85 Based on published literature, GLM with log
function was selected to estimate the incremental expenditure as it resulted in a best-fitting
model. 85-87
Incremental total expenditure for various categories of medical events associated with CF cases
were estimated separately in children (age <18 years) and in adults (age ≥18 years) using GLM
models with log function. The dependent variable was mean cumulative expenditure and the
independent variable was CF (yes/no). Among children, covariates included gender
(male/female), race (White, Black, Hispanic, Asian and others), insurance coverage (private,
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public and uninsured) and asthma as it was the only comorbidity information captured in
children below 18 years. Among adults, covariates included gender (male/female), race (Whites,
Blacks, Hispanics, Asian and others), insurance coverage (private, public and uninsured) and a
comorbidity index score (high blood pressure, multiple diagnosis of high blood pressure,
coronary heart disease, angina, heart attack, other heart disease, stroke, emphysema, high
cholesterol, cancer, diabetes, arthritis, asthma). A comorbidity index score was created by
summing all the comorbid conditions (if present) and categorizing them into three different
groups: comorbidity index score 1-3, comorbidity index score 4-6 and comorbidity index score 7
and above.

PART 2: PHARMACOECONOMIC EVALUATION OF LUMACAFTOR/
IVACAFTOR IN CYSTIC FIBROSIS
Although lumacaftor/ivacaftor has demonstrated higher efficacy, lower side effects, and most
importantly, has offered a new treatment option to patients with CF with F508del mutation, the
estimated drug cost of $270,172.77 in 2016 dollars has become a source of concern for
healthcare stakeholders. Despite the clinical benefits, the high cost of therapy necessitates an
assessment of the overall value of the drug in terms of its cost effectiveness and the financial
impact on health plans.
Economic evaluations are of two types- full and partial. A full economic evaluation compares
both the costs and consequences (effectiveness, benefits) of two or more interventions. These
types of evaluations require the identification, measurement and valuation of both costs and
consequences. There are four full economic evaluations including cost-minimization, cost-
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effectiveness, cost-utility and cost-benefit analyses. These analyses differ in the way in which
the outcomes are measured and reported. 88
Evaluations which address only costs or outcomes are considered to be partial economic
evaluations. 89 These evaluations do not involve a comparison between alternative interventions
or do not relate costs to benefits but these analyses are also useful as they provide elements of
information for a full evaluation. Cost analysis, cost consequence analysis and cost of illness
analysis are few examples of partial economic evaluations. 90

Outcomes
The outcomes of interest in economic evaluations include the average cost-effectiveness ratio,
marginal cost effectiveness ratio and incremental cost-effective a cost-effectiveness ratio. Cost
effectiveness ratio (CER) is a way of calculating the cost per unit of benefit of a drug or an
intervention.
Average CER (ACER)
A CER when calculated relative to no treatment is referred to as an average CER
Average CER = Cost A/Effect A
Marginal CER
A marginal CER refers to the change in costs and health benefits from a one-unit expansion or
contraction of service from a healthcare intervention
Marginal CER = (Cost n*A – Cost (n-1) * A)/Effect n*A – Effect (n-1) *A
In most scenarios, new interventions must be compared to existing therapies through an
incremental cost effectiveness analysis (CEA).
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Incremental CER (ICER)
An incremental CER can be expressed as change in costs and health benefits when one
healthcare intervention is compared to an existing one
Incremental CER= CostA– CostB/EffectA – EffectB
Where effect = natural outcome such as FEV1% predicted values or QALY
A, B are alternative interventions. 91

Components of a cost effectiveness analysis
Patient population and comparator
The first step in an economic evaluation is the identification of a target intervention and a target
patient population. Then appropriate comparator drugs need to be identified. The target
population can be identified from characteristics of patient population used in clinical trials. Ideal
comparator drugs include medications belonging to same therapeutic class of the target
intervention, no drug or an existing standard therapy.
Perspective
Identification of perspective is very important while conceptualizing economic analyses.
Perspective focuses on the viewpoint of stakeholders and dictates what costs are included in the
analysis. Some perspectives include government, provider, third party payer, society, and patient.
•

Government perspective includes all the costs incurred by the government, including
employment costs.

•

Provider perspective includes all inpatient and outpatient costs, including hospital
stay, outpatient visit, medical equipment, costs of medical testing, medications.
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•

Third party payer perspective includes all costs that are reimbursed to providers for
provision of care.

•

Societal perspective is the broadest perspective and includes both direct medical,
nonmedical costs and indirect costs (work productivity loss, caregiver costs).

Time horizon and discounting
The analysis should state clearly the time horizon of the CEA which will cover the time over
which the costs and outcomes will occur. When cost and outcomes occur for an extended period,
discounting should be used to represent the values to current day. Typical discount rates range
from 3 to 6%.
Costs
Costs can be determined in three steps: identification, measurement and valuation. The
perspective of study used in the analysis will determine the type of costs to be included in the
study. Studies conducted from a societal perspective include all costs - including direct, indirect,
and intangible costs whereas studies conducted from a payer perspective includes only direct
medical costs. Direct medical costs include all costs that are attributable to the treatment such as
hospitalization, medication costs, and diagnostic testing. Direct non-medical costs include
transportation costs to and from the hospital/healthcare centers. Indirect costs include loss of
income due to work productivity loss. Intangible costs include costs associated with pain and
suffering.
Sensitivity Analysis (SA)
It is very essential to determine the sensitivity of estimates to variations in costs and outcomes.
Sensitivity analysis is a process of checking the robustness of the results and conclusions of
economic evaluations. It is conducted by varying the underlying assumptions and inputs over a
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range of possible values. The model is considered to be robust if the sensitivity analysis results
are found to be stable over a wide range of input parameters. Different types of sensitivity
analysis used are one-way SA, two-way SA, multi-way SA, tornado analysis and probabilistic
SA. 91

Model design
Two static decision models were developed using Microsoft Excel ® to evaluate the cost
effectiveness and budget impact of lumacaftor/ivacaftor in a hypothetical CF population. Static
models were utilized since the evaluations involved shorter time horizon. Dynamic Markov
models require time dependent transition probabilities and are not available in the literature,
because the drug was approved by the US FDA in 2015 and long-term effectiveness data of the
drug was not available at the time of the study. A shorter time horizon was chosen for the model
to reflect the outcomes and duration of published clinical trials.

Comparators
Lumacaftor/ivacaftor is a CFTR modulator therapy indicated in patients aged 6 years and older
with homozygous F508 del mutation of CFTR gene. Lumacaftor/ivacaftor does not replace any
existing therapy because the drug targets a specific gene mutation. The CEA, therefore,
compared lumacaftor/ivacaftor against placebo and the BIA calculated the pre- and postinclusion of the drug on the formulary along with standard pulmonary therapy that included
bronchodilators, inhaled antibiotics, dornase alfa, inhaled hypertonic saline and inhaled
corticosteroids. 92
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Patient population
The hypothetical patient population in both CEA and BIA analyses was CF patients aged 12
years and older with homozygous F508 del mutation of CFTR gene who were on standard
therapy at baseline and treated by lumacaftor/ivacaftor. The demographics and clinical
characteristics of the study population were based on clinical trial data of lumacaftor/ivacaftor
(Refer Table 9). 92
For BIA, the assumption was that patients continued to receive existing standard pulmonary
therapy consisting of bronchodilators, inhaled antibiotics, dornase alfa, inhaled hypertonic saline
and inhaled corticosteroids even after the introduction of lumacaftor/ivacaftor.
The target population for BIA was calculated based on a total US population of 322,762,018 and
a population of 274,062,018 aged 12 years and above. 93, 94 The prevalence of CF in the entire US
population was estimated as 0.008976%. Using this data, the estimates of CF prevalence in
population 12 years or above was calculated as 24,609 (0.008976%). Similarly, the prevalence of
CF in a hypothetical plan population of one million was estimated at 8,970. Out of 8,970, 7,750
(86.4%) were estimated to have F508 del mutation with 46.1% of those qualifying with
homozygous F508 del mutation, leading to the target population estimation of 3,572. The target
population for BIA is presented in Figure 12.

Perspective
Both models were analyzed from a US third party payer perspective. Direct costs such as drug
acquisition costs, monitoring costs and costs to treat adverse events were included in the
analyses.
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Table 9: Demographics and baseline characteristics of study population
Characteristics
Female: n (%)
Age in years: mean (range)
Subgroup: n (%)
12 to <18 years
≥18 years
FEV1% predicted at baseline:
mean (range)
Subgroup: n (%)
FEV1% predicted <40
FEV1% predicted ≥40 to <70
FEV1% predicted ≥70 to ≤90
FEV1% predicted >90

Placebo
(N=371)
181 (48.8)
25.4 (12-64)

Lumacaftor/ivacaftor
(N=369)
182 (49.3)
25.3 (12-57)

96 (25.9)
275 (74.1)
60.4 (33.9-99.8)

98 (26.6)
271 (73.4)
60.5 (31.3-96.5)

28 (7.5)
238 (64.2)
97 (26.1)
3 (0.8)

29 (7.9)
233 (63.1)
100 (27.1)
3 (0.8)

Source: Wainwright et al., 2016 92
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Figure 12: Target population for budget impact analysis of lumacaftor/ivacaftor
Total US population
322,762,018
Prevalence of CF in the entire US
28,983 (0.008970%)
US population 12 years and above
274,062,018
Prevalence of CF in US population 12
years and above
24,609 (0.008970%)
Hypothetical plan population
1,000,000
Prevalence of CF in plan population
8,970 (0.008970%)
CF population with F508 del mutation
7,750 (86.4%)
CF population with homozygous F508
del mutation
3,572 (46.10%)
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Analytical time frame
Both models were analyzed over a one-year time frame. The shorter time frame was chosen to be
consistent with the length of phase 3 clinical trials and the outcomes data extracted from the
trials. 92 As discussed earlier, long-term clinical efficacy of the drug was not available at the time
of the study.

Efficacy/safety inputs
The FEV1% predicted value was utilized as an efficacy input in the CEA model as it was the
most commonly reported primary outcome in the phase 3 clinical trials of lumacaftor/ivacaftor.
Mean absolute change in FEV1% predicted reported at week 24 in the clinical trials, was utilized
in the analyses. 92 The safety data of the drug included the most common adverse events reported
by subjects in the phase 3 clinical trials. The most common adverse events were defined as those
that occurred in at least 10% of the patients in any treatment group (Refer Table 10). 92

Cost inputs
Drug acquisition costs
The drug acquisition costs were WAC taken from 2015 Redbook®, inflated to 2016 value, using
inflation data from the Bureau of Labor Statistics. Dosage information was taken from published
FDA package inserts and number of doses per package were identified from the Redbook®. The
dosage information was then utilized to calculate the number of packages per year per patient.
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Table 10: Safety/efficacy of lumacaftor/ivacaftor from phase 3 and published clinical trials

Efficacy at week 24
Absolute change in percent
predicted FEV1 from baseline Mean
(SE)

TRAFFIC
Placebo
(n=184)

TRANSPORT
Lumacaftor/ Placebo
Lumacaftor/
ivacaftor
(n=187)
ivacaftor
(n=182)
(n=187)

Pooled analysis
Placebo
Lumacaftor/
(n=371)
ivacaftor
(n=369)

-0.44(0.524)

2.16 (0.530)

-0.15 (0.539)

2.85 (0.540)

-0.29
(0.531)

2.50 (0.534)

-

2.6 (1.2-4.0)

-

3.0 (1.6-4.4)

-

2.8 (1.8-3.8)

112/184
(60.86%) 25
-

73/182
(40.10%) 25
-

139/187
(74.33%) 25
-

79/187
(42.24%) 25
-

182
(49.2%) ^
6
(1.6%) ^

132
(35.8%) ^
17
(4.6%) ^

Percent difference vs. placebo in
absolute change, mean (95% CI)
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Safety at week 48
Participants affected/at risk for
pulmonary exacerbations, n (%)
Participants discontinued because of
an adverse event, n (%)

Source: TRAFFIC: NCT01807923 95; TRANSPORT: NCT01807949 96; CI: confidence interval; SE: standard error
all the values reported from phase 3 TRAFFIC and TRANSPORT trials unless specified; ^ values reported from published clinical
trial, Wainwright et al., 2016 92; the reported adverse events were those that either developed or increased in severity at or after the
time patients received the initial dose of the study drug (placebo or lumacaftor/ivacaftor), up to 28 days after receipt of the last dose;
FEV1% predicted: percent predicted forced expiratory volume in 1 second

For both analyses, the drug acquisition costs were calculated as the product of package cost and
the number of packages required per year over the respective time horizon. Any product rebates,
discounts, patient co-pay or co-insurance were not considered in the analyses. Drug acquisition
costs of lumacaftor/ivacaftor and standard therapy are presented in Table 11.
Monitoring costs
The monitoring schedules utilized in both analyses were taken from the package insert of
lumacaftor/ivacaftor and CF Care Guidelines reported by the 2013 CF Foundation Patient
Registry. 25, 97 Monitoring test schedules associated with lumacaftor/ivacaftor included aspartate
aminotransferase test (AST), alanine aminotransferase test (ALT) and bilirubin which were taken
from package insert. All other laboratory tests were taken from guidelines published by CF
Foundation. 25, 97 Frequency of clinic visits, outpatient visits and inpatient stays were taken from
published literature. 25, 97 The costs for laboratory and monitoring tests were obtained from the
2016 Physician Fee Schedules of Centers for Medicare and Medicaid (CMS) using the Current
Procedural Terminology (CPT) codes for each test, healthcare blue book (2016), and from
published literature. 98, 99 The monitoring test schedules and annual costs are presented in Table
12 and the probabilities of medical and adverse events are presented in Table 13

Outcome measures
The outcomes of interest for CEA included cost of therapy per patient, ACER presented as cost
per FEV1% predicted per patient, and ICER presented as additional cost per one-unit increase in
FEV1% predicted per patient.


Total cost of therapy: sum of all the costs involved in treatment by placebo or
lumacaftor/ivacaftor.
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Table 11: Dosing and acquisition costs of medications
Drug

Dose,
frequency,
route
400 mg
lumacaftor/250
mg ivacaftor,
Q12 hours PO12
hours

Doses
per pack
112

Whole sale acquisition Packages
price per package ($) needed per
year
19,923.08
13.03

Whole sale
acquisition price per
year 2016 ($)
270,172.77

Bronchodilator
Albuterol (Proventil HFA®) 100

0.18 mg
Q6 hours
inhalation

74,444

75.36

0.039

2.93

Inhaled antibiotic
Tobramycin
(TOBI®) 101

300 mg
Q12 hours
inhalation

56

3,604

13

46,852

Mucolytic agent
Dornase alfa (Pulmozyme®) 102

2.5 mg
Q daily
inhalation
10 ml of 6%
solution
Q12 hours
inhalation

30

3,283.41

12.16

39,926.26

24

40.00

30.4

1,216.00

200 mcg
Q daily
inhalation

9.9

11.84

147.4

1,745.21

Lumacaftor/ivacaftor
Orkambi®
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Mucolytic agent
Hypertonic saline
(Nebusal®) 103
Inhaled corticosteroid
Fluticasone (Flonase®) 104

Source: Wainwright et al., 2016 92; PO = by mouth; Q: every

Table 12: Monitoring costs
Probability
Drug monitoring
AST
ALT
Bilirubin
Sputum/throat cultures
Lung function tests /PFT
Influenza Vaccine (flu shot)
Fat soluble vitamins blood levels
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Oral glucose tolerance test
Clinic visits

^

0.56

CPT code

Frequency Unit cost
2016 ($)

84450 105
84460 107
82247 109
87070, 87205 111

4
4
4
4

14 106
14 108
13 110
158.40 112

56
56
52
633.6

94010 113
90656 115
A: 84590 117
D: 82306 118
E: 84446 119
K: 84597 120
82951, 82952 125
99205 (initial),
99215 (subsequent)

2
1
2

36.52 114
24 116
A: 31 121
D: 100 122
E: 37 123
K: 36 124
34 126

73.04
24
408

1
4.39 31

127
^

562.5*

Annual
cost 2016
($)

34
1,382.85

Outpatient visits
Inpatient stays

0.55
0.28^

6.26 31
0.64 127

291.18*
7,377.05*

1,002.53
1,321.96

Adverse events
Pulmonary exacerbations in placebo
group

0.39#

3.6 128

13,612.65 129

19,112.14

Pulmonary exacerbations in
0.31#
3.6 128
13,612.65 129 15,191.71
lumacaftor/ivacaftor group
^Calculated using rate of medical events from O'Sullivan et al., 2011 31; * calculated as a part of objective 1 using MEPS 2014 data
and inflated to 2016; #: calculated using rate of pulmonary exacerbations in placebo group and lumacaftor/ivacaftor group reported
in phase 3 clinical trial

Table 13: Probabilities of medical events and adverse events
Variable

Medical events
Clinic visits
Outpatient visits
Inpatient stays
Adverse events
PE in
lumacaftor/ivacaftor
group
PE in placebo group

Number
Disc
considered
for
analysis

Number with
the event

Group
followed
until

Patient
years

Rate of
event

Probability

1,064
1,064
1,064

0
0
0

862 (81.01%)
860 (80.8%)
359 (33.76%)

1 year
1 year
1 year

1,064
1,064
1,064

0.810
0.808
0.337

1-0.444= 0.555
1-0.445= 0.554
1-0.713= 0.286

371

6

182

0.9 years

334

185/334=
0.55

1-0.609 = 0.391

369

17

132

0.9 years

332

140.5/332= 1-0.685= 0.314
0.42
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Source: O'Sullivan et al., 2011 31; Wainwright et al., 2016 92 disc: discontinued; PE: pulmonary exacerbation;* half considered to be
followed until 24 weeks; patient years: number considered for analysis * time followed; rate of event: number with event/ patient
years; probability: 1-e –r* t, where r: rate of medical event, t: time horizon (1 year)



ACER: total cost of therapy/ FEV1% predicted at week 24 from pooled analysis of phase
3 clinical trials.



ICER: (cost lumacaftor/ivacaftor - cost placebo)/ (outcome lumacaftor/ivacaftor - outcome placebo)

Where outcome = FEV1% predicted at week 24 from pooled analysis of phase 3 clinical trials
The outcomes of interest for BIA included total budget impact, PMPM cost and PTMPM cost.


Total budget impact: difference in budget pre-and post-inclusion of
lumacaftor/ivacaftor to the health plan formulary with existing standard therapy.



PMPM cost: total budget impact/ total hypothetical plan population



PTMPM cost: total budget impact/ total target population

Sensitivity analysis
Univariate sensitivity analyses were conducted to test the model assumptions and uncertainty in
certain model variables, to determine the impact of varying the model inputs on the CEA and
BIA of lumacaftor/ivacaftor. Drug acquisition costs, monitoring costs and cost to treat
pulmonary exacerbations were varied over a range of estimates (±25 %) to test the robustness of
the results based on the ranges used in the literature. 130-132 However, costs due to medical events
including clinic visits, outpatient visits and inpatient stays were assumed to decline by 10% in
lumacaftor/ivacaftor group and hence, sensitivity analyses for these variables was conducted at 10% and -25%.

Model assumptions
Several assumptions were made in the study. First, a recently published study reported the mean
weighted medication possession ratio (MPR) of the CF population on lumacaftor/ivacaftor to
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range from 87% to 99.5% with a mean MPR of 92.28%. 133 To provide a fair comparison and to
avoid preference to lumacaftor/ivacaftor therapy, adherence to lumacaftor/ivacaftor, placebo
(CEA), and standard therapy (BIA) were all assumed to be 100%. Second, the prevalence of CF
was based on the latest estimates available from 2015 CF Foundation Patient Registry Annual
Report and it was assumed to be same in 2016 as well. Third, patients were assumed to be
maintained on the assigned therapy throughout the duration of the model. Fourth, clinical inputs
such as FEV1% predicted values and pulmonary exacerbation rates taken from published phase 3
clinical trials were assumed to be highly reliable and valid. Fifth, because the analyses had a
short analytic frame, it was assumed that the disease condition of the patient remained the same
and the patient did not transition to a higher level of disease severity. Sixth, in CEA, subjects
were assumed to be on standard therapy at baseline which included pulmonary maintenance
medications. Finally, for both analyses, costs due to medical events including clinic visits,
outpatient visits and inpatient stays were assumed to decline by 10% after the initiation of
lumacaftor/ivacaftor therapy. The cost of pulmonary exacerbations was adjusted based on the
probabilities obtained from published clinical trials.
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CHAPTER FOUR: RESULTS

Although CF results in the use of more healthcare resources, recent estimates of the economic
burden of CF is lacking. Novel CFTR therapies like ivacaftor and lumacaftor/ivacaftor have
shown a tremendous improvement in FEV1% predicted rates from baseline in phase 3 clinical
trials but the cost effectiveness of the lumacaftor/ivacaftor therapy has not been reported in the
US. Thus, the overall objective of this study was to estimate the burden of illness in CF patients
and to understand the overall effectiveness and affordability of lumacaftor/ivacaftor therapy.
Results from the study are reported in this section

PART 1: BURDEN OF ILLNESS IN CYSTIC FIBROSIS

Demographics and clinical characteristics of adult CF cases and controls
A descriptive analysis was conducted on 2010-2014 MEPS data to understand the demographics
and clinical characteristics of CF cases and controls. The number of records identified with a
diagnosis code of CF were 22, 24, 49, 46 and 38 for the years 2010, 2011, 2012, 2013 and 2014,
respectively. Unique records of 130 (72.6%) unique individuals were identified from the total
179 records. Further, only 109 (83.8%) of the 130 records reported using at least one CF-related
medical service.
Of the 109 records, 78 (71.5%) were identified as adults (age ≥18 years). The number of records
identified for control sample in 2010, 2011, 2012, 2013 and 2014 were 102,284, 108,595,
118,801, 123,829 and 116,641 respectively. A total of 570,150 discharge records of controls
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were identified, of which 85,521 (14.9%) were identified as being unique. Further, 60,871
(71.1%) were identified as adults.
Demographic and clinical characteristics of adult CF cases and controls are presented in Table
14. Ages of cases ranged from 18-82 years with an average of 50.55 ±17.04 years and the ages of
control group ranged from 18-85 years with a mean of 46.85 ± 18.03 years. There was no
significant difference in the mean age between CF cases and controls (t statistic: -1.81,
p=0.0703). The average household income was also similar with $61,872.46 among cases and
$61,182.67 among controls (t statistic: -0.11, p=0.9148).
Both cases (67.95%) and controls (55.99%) were predominantly female and majority were
Whites (65.14%, 28.64%, respectively). Descriptive analysis on marital status showed that
52.38% of cases were married and 47.62% were unmarried whereas among control group,
48.24% were married and 36.79% was unmarried. It was also observed that only 1 (1.28%) out
of 78 CF cases was uninsured, but the uninsured proportion was comparatively higher among
controls (15.77%). MEPS captured information related to fewer comorbidities including
cardiovascular diseases, respiratory diseases like asthma and emphysema, diabetes, high
cholesterol, arthritis, and cancer. The most commonly reported comorbidities among cases and
controls were hypertension (50%, 30.46%, respectively), high cholesterol (46.15%, 33.09%,
respectively) and arthritis (41.03%, 27.85%, respectively). Results of the chi-square analyses
reported significant association between gender (chi-square value: 4.5235, p=0.0334*), race
(chi-square value: 18.3170, p=0.0011*), insurance coverage (chi-square value: 13.7497,
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Table 14: Demographic and clinical characteristics of adult cystic fibrosis cases and controls
Cases (N=78)
Individual
characteristics

Controls (N=60,871)

Test
statistic

P value

Age

Mean: 50.55 ±17.04 years

Mean: 46.85 ± 18.03 years

-1.81

0.0703

Gender

Male: 25 (32.05%)
Female: 53 (67.95%)
White: 40 (51.28%)
Black: 10 (12.82%)
Hispanic: 4 (5.12%)
Asian: 1 (1.28%)
Others: 1 (1.28%)
Missing: 22 (28.20%)
Mean: $61,872.46 ± 55,240.25
(95% CI: $49,417.71, $74,327.21)

Male: 26,791(44.01%)
Female: 34,080 (55.99%)
White: 19,223 (31.57%)
Black: 8,693 (14.28%)
Hispanic: 10,764 (17.68%)
Asian: 2,919 (4.79%)
Others: 1,114 (1.83%)
Missing: 18,158 (29.83%)
Mean: $61,182.67 ± 56,904.26
(95% CI: $56,904.26, $61,634.73

4.5235

0.0334*

-0.11

0.9148

Married: 11 (14.10%)
Not married: 9 (11.5%)
Missing: 57 (73%)
Any private: 58 (74.36%)
Public only: 19 (24.36%)
Uninsured: 1 (1.28%))

Married: 8,941(14.68%)
Not married: 9,952 (16.34%)
Missing: 42,338 (69.55%)
Any private: 35,651(58.57%)
Public only: 15,619 (25.66%)
Uninsured: 9,601 (15.77%)

1.7493

0.7817

45 (57.69%)

22,812 (37.48%)

13.6074

0.0087*

39 (50.00%)

18,541 (30.46%)

15.9239

0.0071*

Race
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Household
income
Marital status

Insurance
Coverage

18.3170

13.7497

0.0011*

0.0010*

Comorbidities#
High blood
pressure
Multiple
diagnosis of
high blood
pressure
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Coronary heart
disease

9 (11.54%)

3,802 (6.25%)

3.7601

0.4394

Angina

5 (6.41%)

1,694 (2.78%)

3.8228

0.4305

Heart attack
(MI)

5 (6.41%)

2,542 (4.18%)

1.0029

0.9094

Other heart
disease

21 (26.92%)

6,805 (11.18%)

Stroke

6 (7.69%)

2,724 (4.48%)

1.9121

0.7519

Emphysema

6 (7.69%)

1,431 (2.35%)

9.6831

0.0461*

High
cholesterol
Cancer

36 (46.15%)

20,144 (33.09%)

6.0526

0.1953

12 (15.38%)

5,956 (9.78%)

2.7995

0.5919

Diabetes

12 (15.38%)

7,309 (12.01%)

0.8644

0.9296

Arthritis

32 (41.03%)

16,954 (27.85%)

6.7557

0.1494

Asthma

13 (16.67%)

6,360 (10.45%)

3.2394

0.5186

19.4358

0.0006*

Not married includes divorced, separated, never married, widowed; #: not mutually exclusive; test statistic is chi square value for all
categorical variables and t value for all continuous variables; p value significance at 0.05

p=0.0010*), comorbidities like hypertension (chi-square value: 15.9239, p=0.0071*),
emphysema (chi-square value: 9.6831, p=0.0461*), and other heart diseases (chi-square value:
19.4358, p=0.0006*) and occurrence of CF in adults.

Demographics and clinical characteristics of child CF cases and controls
Demographics and clinical characteristics of child CF cases and controls are presented in Table
15. The variables included age, gender, race, household income, marital status, insurance
coverage and comorbidity (asthma). There were 31 child CF cases and 24,650 controls. The ages
among cases and controls ranged from 0-17 years with the mean age being 4.87 ± 5.75 years in
cases and 8.35 ± 5.35 years in controls. There was a significant difference in the mean age
between cases and controls (t statistic: 3.62, p=0.0003*). The average household income was
similar with $54,718.06 among cases and $55,516.44 among controls (t statistic: 0.08,
p=0.9356).
Among cases, the gender distribution was almost equal with males being 15 (48.39%) and
females being 16 (51.61%), but controls had slightly more males (51.29%) than females.
Majority of the controls were under 16 years of age (87.55%), however, a minor proportion of
controls was married (0.56%). It was also observed that none of the cases were uninsured. Half
of the cases had public insurances and half of them had private insurances. But the uninsured
proportion was comparatively higher among controls (4.72%). However, 52.95% of controls had
public insurances and 42.33% had private insurances. 19.35% among cases and 13.62% among
controls had asthma. Information on other existing comorbid conditions among children was not
captured by MEPS. Results of the chi-square analyses did not report any association between
gender, race, insurance coverage, marital status, asthma and occurrence of CF in children.
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Table 15: Demographic and clinical characteristics of child cystic fibrosis cases and controls
Individual
characteristics

Cases (N=31)

Controls (N=24,650)

Test statistic

P value

Age

Mean: 4.87 ± 5.75 years

Mean: 8.35 ± 5.35 years

3.62

0.0003*

Gender

Male: 15 (48.39%)
Female: 16 (51.61%)
White: 14 (45.16%)
Black: 1 (3.22%)
Hispanic: 7 (22.58%)
Asian: 1 (3.22%)
Others: 1 (3.22%)
Missing: 7 (22.58%)
Mean: $54,718.06 ± 55,094.14
(95% CI: $34,509.37, $74,926.76)

Male: 12,642 (51.29%)
Female: 12,008 (48.71%)
White: 5,273 (21.39%)
Black: 3,210 (13.02)
Hispanic: 6,168 (25.02%)
Asian: 808 (3.27%)
Others: 857 (3.47%)
Missing: 8,334 (33.80%)
Mean: $55,516.44 ± 54,969.31
(95% CI: $54,830.20, $56,202.69)

0.1041

0.7469

Married: 0
Not married: 0
Under 16 years: 5 (100%)
Missing: 26
Any private: 15 (48.39%)
Public Only: 16 (51.61%)
Uninsured: 0
6 (19.35%)

Married: 36 (0.56%)
Not married: 768 (11.88%)
Under 16 years: 5,655 (87.55%)
Missing: 18,191
Any private: 10,435 (42.33%)
Public Only: 13,052 (52.95%)
Uninsured: 1,163 (4.72 %)
3,358 (13.62%)

0.7108

Race

Household income
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Marital status

Insurance Coverage
Asthma

8.5021

0.08

1.7411
0.9688

0.0748

0.9356
0.9824

0.4187
0.9145

Not married includes divorced, separated, never married, widowed; test statistic is chi square value for all categorical variables and t
value for all continuous variables; p value significance at 0.05

Resource utilization among cases
Unweighted total OOP expenditure for all medical events was $31,828.58 of which 57.5%
($18,328.66) was accounted by prescription medications followed by 23.3% ($7,419.71) by
office visits. Weighted total OOP expenditure representing OOP payment for the entire US
population was $615,098,138 (Refer Table 16).
Unweighted total cumulative expenditure for all medical events was $455,539.70 of which
33.0% ($150,634.2) was contributed by prescription medications followed by 31.5%
($143,341.3) by inpatient stays. Weighted total cumulative expenditure representing cumulative
payment for the entire US population was $6,691,134,764 (Refer Table 17).
The total OOP and cumulative expenditures were highest in the year 2012 contributing 40.5%
and 34.4%, respectively (Refer Table 18). Expenditures for different medical services each year
are presented in Appendices Table 33
Prescription medicines contributed the highest to total OOP and cumulative expenditure from
2010-2014. Drug classes attributable to higher cumulative expenditure were pulmonary
medications ($85,555.33), gastro intestinal agents ($17,255.25), immune modulators
($14,596.2), antibiotics ($14,186.42) and pain medications ($2,653.53). (Refer Appendices
Table 35 for complete list and description of drug classes).
Some medications were more frequently used and some were attributable to high cumulative
expenditure despite infrequent utilization indicating higher cost of those medications (Refer
Appendices Table 34 for complete list). The most frequently used medications were metformin
(9.4%), levocarnitine (7.9%), respiratory agents (7.8%), prednisone (3.8%), Creon® (3.6%), and
allopurinol (2.5%) (Refer Appendices Table 34 for complete list).
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Table 16: Out-of-pocket expenditure of medical events (2010-2014)
Medical event

Office visits
Home health
Prescription
medications
Inpatient stays
Outpatient visits
Emergency visits
Sum

Out-of-pocket expenditure from 2010-2014 ($)
Unweighted
Weighted
Mean
Total
Mean

Total

87.30 (43.25-131.33)
24.50 (0-102.46)
229.11 (23.58-434.64)

7,419.71
98
18,328.66

101.17 (39.38-162.97)
68.75 (0-160.00)
371.56 (0-767.00)

105,795,071
4,377,427
433,098,457

65.06 (3.72-126.41)
226.32 (0-518.35)
23.94 (0-62.61)
-

715.73
4,979.17
2,87.31
31,828.58

46.85 (0-105.50)
186.07 (0-419.90)
13.14 (0-40.26)
-

6,412,171
63,645,296
1,769,716
615,098,138
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Mean: mean costs for all the observations of a medical event in a year; total: sum of costs for all the observations of a medical event
in a year; out-of-pocket: expenditure paid directly by an individual

Table 17: Cumulative expenditure of medical events (2010-2014)
Medical event

Office visits
Home health
Prescription
medications
Inpatient stays
Outpatient visits
Emergency visits
Sum

Cumulative expenditure from 2010-2014 ($)
Unweighted
Mean

Total

Weighted
Mean

Total

769.53 (342.21-1,196.85)
4,362.50 (0-9,681.97)
1,882.93 (538.49-3,227.37)

65,410.35
17,450
150,634.2

777.49 (194.80-1,360.18)
5,861.76 (4,221.79-7,501.73)
2,046.10 (143.38-3,948.82)

812,971,988
373,213,579
2,385,010,201

13,031.02 (3,450.11-22,611.93)
3,268.98 (0-7,517.78)
565.53 (157.57-973.49)
-

143,341.3
71,917.52
6,786.38
455,539.70

16,070 (0-32,402.03)
2,481.51 (0-5,893.63)
535.14 (57.518-1,012.76)
-

2,199,126,682
848,785,772
72,026,542
6,691,134,764
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Mean: mean costs for all the observations of a medical event in a year; total: sum of costs for all the observations of a medical event
in a year; cumulative: expenditure paid by an individual and payments by private insurance, Medicare, Medicaid and other sources.

Table 18: Out-of-pocket and cumulative expenditures for all medical events from 20102014
Year

2010
2011
2012
2013
2014
Total

Total out-of-pocket expenditure for
all medical events) ($)
Unweighted
Weighted
1,011.98
15,697,839
3,835.34
40,815,097
12,878.75
255,766,819
5,354.42
53,153,619
8,734.59
249,258,850
31,828.58
615,098,138

Total cumulative expenditure for all
medical events) ($)
Unweighted
Weighted
16,013.54
195,618,996
46,368.86
413,793,959
156,688.8
2,883,703,057
94,148.59
924,855,899
141,922.4
2,261,164,451
455,539.7
6,691,134,764

Out-of-pocket: expenditure paid directly by an individual; cumulative: expenditure paid by an
individual and payments by private insurance, Medicare, Medicaid and other sources
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Medications attributable to higher cumulative expenditure were respiratory agents, Creon®,
aminoglycosides, immunologic agents, Myfortic®, selective immunosuppressants, Xopenex®,
Spiriva®, Oxycontin®, levocarnitine (Refer Appendices Table 34 for complete list).
Of the total unweighted cumulative expenditure of $150,634.2 for prescription medications from
2010-2014, $134,216.86 was due to medications used in CF treatment. Respiratory agents
accounted for highest cumulative expenditure of $78,316.47 (Refer Table 19).

Incremental cost burden in CF cases
Table 20 presents the results of regression analysis of incremental expenditure in children with
CF in comparison to children without CF. After adjusting for covariates such as gender, race,
insurance and comorbid condition asthma, the mean cumulative expenditure in children with CF
was 3.67 times of expenditure in children without CF (p=<0.0001*). In general, expenditure in
males was 1.13 times of that of females (p=<0.0001*). Expenditure in Hispanics, Blacks, Asians
and others was 0.65, 0.90, 0.64 and 0.70 times of cumulative expenditure in Whites.
(p=<0.0001*, 0.0024*, <0.0001*, <0.0001*, respectively). Expenditure in children with private
insurance and public insurance was 1.35 and 1.16 times of that of children without insurance
(p=<0.0001*, 0.0187*, respectively). Children with asthma had expenditure which was 1.47
times of that of children without asthma (p=<0.0001*).
Table 21 presents the results of regression analysis of incremental expenditure of adults with CF
in comparison to adults without CF. After adjusting for covariates such as gender, race,
insurance and comorbidity index score, the mean cumulative expenditure in adults with CF was
1.49 times of expenditure in adults without CF (p=0.0618). In general, expenditure in males was
0.95 times of that of females (p=0.0207*).
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Table 19: Cumulative expenditure of prescription medications used in cystic fibrosis from
2010-2014
Name of the
medication
Respiratory agents

Drug class

Use/category of drug

Respiratory agent

Creon

Gastro intestinal
agent
Antibiotic

Drugs or a combination of
drugs used to prevent, relieve
or treat respiratory diseases
Enzyme replacement therapy
for pancreatic insufficiency
Antibiotic, to treat pulmonary
exacerbations of CF/ to treat
Pseudomonas aeruginosa
infection
Modifies immune response

Aminoglycosides

Immunologic agents
Myfortic

Immune
modulator
Immune
modulator

Selective
immunosuppressants
Xopenex
Spiriva
Prevacid

Immune
modulator
Respiratory agent
Respiratory agent
Gastro intestinal
agent

Hormones/hormone
modifiers
Singulair
Azithromycin

Hormone
modifier
Respiratory agent
Antibiotic

Phlexy-10
Epipen-JR

Dietary
supplement
Respiratory agent

Minocycline

Antibiotic

Dexamethasone

Antiinflammatory
agent
Respiratory agent

Mycophenolate

Total cumulative
expenditure ($)
78,316.47
15,170.16
13,307.2

6,176.5

Immunosupressive, prevents
organ rejection after
transplant
Suppresses immune system to
fight infections
Bronchodilator
Bronchodilator
To treat stomach ulcers,
gastro esophageal reflux
disorder
Modifies hormone levels
inside the body
To treat allergies, asthma
Antibiotic, to treat CF lung
disease
Low protein diet

4,392.94

To treat asthma attacks, vaso
constrictor
To treat bacterial infections
such as urinary tract
infections, respiratory
infections, skin infections,
severe acne, gonorrhea, tick
fever, chlamydia, and others
Steroid, anti-inflammatory

317.33

To treat asthma

275.06
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3,824.6
3,281.6
2,223.36
1,552.48
769.05
642.1
455.5
375

296.92

279.88

Albuterol
Pancrealipase
Methotrexate
Flovent HFA
Pentoxifylline
Prednisone
Adipex-p
Folgard Rx
Lansoprazole
Qvar
Polyethylene glycol
Cephalexin
Folbic
Optichamber
Lactulose
Cyanocobalamin
Mag-ox 400
Amoxicillin
Culturelle
Aero chamber
Vitamin D
Fluticasone
Phentermine
Spacer inhaler
(Optichamber)
Multivitamin

Respiratory agent
Gastro intestinal
agent
Immune
modulator
Respiratory agent
Antiinflammatory
agent
Antiinflammatory
agent
Weight loss
supplement
Dietary
supplement
Gastro intestinal
agent
Medical device
Gastro intestinal
agent
Antibiotic
Dietary
supplement
Medical device
Gastro intestinal
agent
Dietary
supplement
Dietary
supplement
Antibiotic
Dietary
supplement
Medical device
Dietary
supplement
Respiratory agent
Weight loss
supplements
Medical device
Dietary
supplement

Bronchodilator
Enzyme replacement therapy

259.92
249.78

Immunosupressive,
chemotherapy
Steroid and decongestant
Anti-inflammatory, vaso
dilator

202.16

Steroid, anti-inflammatory

150.76

Promotes weight loss

149.97

Vitamin complex, to treat
vitamin deficiency
Proton pump inhibitor to treat
stomach ulcers
Aerosol, inhaler
Laxative

142.97

Antibiotic, treats pulmonary
exacerbations of CF
Multivitamin, to treat vitamin
deficiency
Inhaler
Laxative

84.8

To treat vitamin deficiency

48.44

Antacid to relieve heart burn,
indigestion, acid indigestion
Antibiotic
Probiotic for digestive system

43.5

Aerosol
To treat vitamin deficiency

35.03
33.74

Steroid, decongestant
Promotes weight loss

31.58
23.39

Inhaler

21.29

To treat vitamin deficiency

19.96
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188.91
180.54

125.82
111.55
89.14

61.29
53.98
53.43

42
37.38

Vortex/mask
Tri-vitamin
Ibuprofen
Vitamin B12
Pantoprazole
Sodium Chloride
Aspirin

Medical device
Dietary
supplement
Antiinflammatory
agent
Dietary
supplement
Gastro intestinal
agent
Respiratory agent
Antiinflammatory
agent
Respiratory agent

Cheratussin AC
Vitamin B6

Dietary
supplement
Dietary
supplement

Niacin

Helps in inhalation
To treat vitamin deficiency

19.91
18.99

Non-steroidal antiinflammatory drug

16

To treat vitamin deficiency

16

Proton pump inhibitor, to treat
stomach ulcers
Mucolytic, to maintain levels
of sodium
Non-steroidal antiinflammatory drug, blood
thinner, prevents heart stroke
Cough suppressant,
expectorant
To treat vitamin deficiency

14.45

To treat vitamin deficiency

2.23

Total

10
9.75
9
3.06

134,216.86

Table 20: Regression analysis to estimate the incremental direct medical expenditure in
children with cystic fibrosis compared to children without cystic fibrosis
Parameter
CF
Male
Hispanic
Black
Asian
Others
Any private
Public only
Asthma

Reference
category
No CF
Female
White
Uninsured
No Asthma

Parameter
estimate
3.67
1.13
0.65
0.90
0.64
0.70
1.35
1.16
1.47

P value
<0.0001*
<0.0001*
<0.0001*
0.0024
<0.0001*
<0.0001*
<0.0001*
0.0187*
<0.0001*

CI: confidence interval; SE: standard error; p value significant at ≤0.05
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Table 21: Regression analysis to estimate the incremental direct medical expenditure in
adults with cystic fibrosis compared to adults without cystic fibrosis
Parameter

Reference
category
No CF
Female
White

CF
Male
Hispanic
Black
Asian
Others
Any private
Uninsured
Public only
Comorbidity index 4- Comorbidity
6
index 1-3
Comorbidity index 7
and above

Parameter
estimate
1.49
0.95
0.77
0.91
0.82
0.91
2.10
2.39
2.02
3.65

P value
0.0618
0.0207*
<0.0001*
0.0001*
<0.0001*
0.1546
<0.0001*
<0.0001*
<0.0001*
<0.0001*

CI: confidence interval; SE: standard error; †: reference category; p value significant at ≤0.05
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Expenditure in Hispanics, Blacks, Asians and others was 0.77, 0.91, 0.82 and 0.91 times of
cumulative expenditure in Whites. (p=<0.0001*, 0.0001*, <0.0001*, 0.1546, respectively).
Expenditure in those with private insurance and public insurance was 2.10 and 2.39 times of
those without insurance (p=<0.0001*, <0.0001*, respectively). Expenditure in those with
comorbidity index score 4-6 was 2.02 times and with comorbidity index score 7 and above was
3.65 times of those with comorbidity index score 1-3 (p=<0.0001*, <0.0001*).
Table 22 describes the results of incremental expenditure in children with CF compared to
children without CF. Children with CF had a mean cumulative expenditure of $13,990 where as
children without CF had a mean cumulative expenditure of $3,231.27. Comparison of means
between cases and controls using independent sample t test reported significant difference in
mean cumulative expenditure between the two groups (t value: -4.26, p= <0.0001*).
Mean cumulative expenditure for all medical events across five years was $16,975.80 in adults
with CF and $8,859.87 in adults without CF. Comparison of means between cases and controls
using independent sample t test reported significant difference in mean cumulative expenditure
between the two groups (t value: -3.12, p=0.0018*).
The analysis of incremental cost burden in children and adults show that the expenditure in cases
was higher than in controls and the costs were higher in adults when compared to children. These
results are different from those obtained in previous studies as they suggested higher expenditure
in children than in adults. 32
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Table 22: Comparison of cumulative expenditure among children with and without cystic
fibrosis
N
Children
Without
CF
With CF

24,650

Adults
Without
CF
With CF

60,871

31

78

Cumulative expenditure ($)
Mean (SE)
95% CI
3,231.27 (89.43)

3,055.99, 3,406.55

13,990 (3,764.18)

6,302.52,
21,677.48

8,859.87 (93.10)

8,677.39, 9,042.36

16,975.80
(2,735.67)

11,529.60 22,422.00

DF

t value

p value

24679

-4.26

<0.0001*

60947

-3.12

0.0018*

Cumulative: expenditure paid by an individual and by other sources like insurance; mean: mean
expenditure in children for all medical events between 2010 and 2014; total: total expenditure in
children for all medical events between 2010 and 2014; SE: standard error; CI: confidence
interval; equal variances assumed for t test; p value significant at ≤0.05
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PART 2: PHARMACOECONOMIC EVALUATION OF
LUMACAFTOR/IVACATTOR

Base-case analysis of cost effectiveness of lumacaftor/ivacaftor
The cost of therapy per patient in the lumacaftor/ivacaftor was $379,780.11 compared to
$113,734.54 in the placebo group. The ACER in patients treated by lumacaftor/ivacaftor was
$151,912.04 indicating a positive change in FEV1% predicted value from baseline. The ACER
for placebo was -392,188 indicating the amount spent to receive a single unit of negative
outcome i.e. FEV1% predicted value. The estimated ICER of lumacaftor/ivacaftor over placebo
was $95,016.28 indicating that one-unit positive change in FEV1% predicted value by
lumacaftor/ivacaftor was achieved for each additional $95,016.28

Sensitivity analysis of cost effectiveness of lumacaftor/ivacaftor
The results of one-way sensitivity analyses showed that the ICER of lumacaftor/ivacaftor was
stable to changes in most input parameters. However, after a ±25% change in the cost of
lumacaftor/ivacaftor, the drug had an ICER ranging from $70,893.72 to $119,138.87. Similarly,
lumacaftor/ivacaftor was sensitive to cost of standard therapy with the ICER ranging from
$87,003.57 to $103,029, followed by change in cost to treat pulmonary exacerbations with the
ICER ranging from $93,659.88 to $96,372.68, and probability of occurrence of pulmonary
exacerbations with the ICER ranging from $93,791.14 to $96,241.42. The ICER of
lumacaftor/ivacaftor was not affected by varying the cost of other variables and probabilities of
occurrence of medical events. These results suggested that the baseline cost-effectiveness model
was robust to changes in most of the input parameters except, drug cost, cost of standard therapy
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and cost to treat, probability of pulmonary exacerbations. Tables 23 and 24 present results of
sensitivity analysis of placebo. Tables 25 and 26 present results of sensitivity analysis of
lumacaftor/ivacaftor. Figure 13 presents the tornado plot of one way-sensitivity analysis of cost
effectiveness of lumacaftor/ivacaftor. Increased (high) and decreased (low) input ranges were
plotted to determine the effect of different variables on the ICER. The results suggested that even
after varying the data input ranges, lumacaftor/ivacaftor therapy was stable to most of the
variables except for the cost of drug, standard therapy and pulmonary exacerbations. Refer
Appendices Table 36 for impact of variables on ICER value.

Base-case analysis of budget impact of lumacaftor/ivacaftor
The cost of therapy per patient due to standard therapy alone before the inclusion of
lumacaftor/ivacaftor was $113,734.52 and after the inclusion of lumacaftor/ivacaftor on the
formulary was $379,780.11. Hence, the total budget impact due to inclusion of the drug on the
formulary was $266,045.59. Based on a one million hypothetical plan population, the PMPM
cost was $0.022 and the PTMPM cost was $6.2067 based on a target population of 3,572.

Sensitivity analysis of budget impact of lumacaftor/ivacaftor
The results of one-way sensitivity analysis showed that the PTMPM cost of lumacaftor/ivacaftor
was most likely to be influenced by change in certain input parameters. After a ±25% change in
cost of lumacaftor/ivacaftor, the drug had PTMPM cost ranging from $4.1076 to $8.3059.
Similarly, lumacaftor/ivacaftor was slightly sensitive to change in cost to treat pulmonary
exacerbations with PTMPM cost ranging from $6.1181 to $6.2953 and probability of occurrence
of pulmonary exacerbations with PTMPM cost ranging from $6.1153 to $6.2868.
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Sensitivity analysis of placebo

Table 23: Costs
Variable

Base case

Low

High

ICER at
low

ICER at high

Standard
89,742.40
therapy
Monitoring costs

67,306.80

112,178

103,029

87,003.57

Sputum
culture
PFT’S

633.6

475.2

792

95,072.85

94,959.71

73.04

54.78

91.3

95,022.81

95,009.76

Flu shot

24

18

30

95,018.43

95,014.14

Fat soluble
vitamins
OGT

408

306

510

95,052.71

94,979.86

34

25.5

42.5

95,019.32

95,013.25

Clinic visits

1,382.25

1,037.13

1,728.56

95,139.75

94,892.82

Outpatient
1,002.53
751.89
visits
Inpatient
1,321.96
991.47
stays
Costs to treat adverse events

1,253.16

95,105.79

94,926.77

1,652.45

95,134.32

94,898.25

PE

23,890.17

96,722.72

93,309.84

Drug costs

19,112.14

14,334.11

Sensitivity analysis conducted at low (-25%) and high (+25%); %); PFT: pulmonary lung
function test; OGT: oral glucose tolerance test; PE: pulmonary exacerbations
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Table 24: Probabilities of medical events
Variable
Clinic visits
Outpatient
visits
Inpatient
stays
PE

Probability
Base case
0.56

Probability
low
0.42

Probability
high
0.70

Base case

low

high
1,728.25

ICER at
low
95,139.82

ICER at
high
94,892.93

1,382.25

1,036.95

0.55

0.41

0.69

1,002.53

747.33

1,257.71

95,221.51

95,039.23

0.28

0.21

0.35

1,321.96

991.47

1,652.45

95,134.32

94,898.25

0.39

0.30

0.48

19,112.14

14,701.66

23,522.65

96,591.46

93,441.10

Sensitivity analysis of probabilities conducted at low (-25%) and high (+25%); PE: pulmonary exacerbations
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Sensitivity analysis of lumacaftor/ivacaftor

Table 25: Costs
Variable

Base case

Low

High

ICER at
low

ICER at high

Lumacaftor
270,172.8
/ivacaftor
Standard
89,742.40
therapy
Monitoring costs

202,629.60

337,716

70,893.72

119,138.87

67,306.80

112,178

87,003.57

103,029

AST
ALT
Bilirubin

56
56
52

42
42
39

70
70
65

95,011.28
95,011.28
95,011.64

95,021.28
95,021.28
95,020.93

Sputum
culture
PFT’S

633.6

475.20

792

94,959.71

95,072.86

73.04

54.78

91.3

95,009.76

95,022.81

Flu shot

24

18

30

95,014.14

95,018.43

Fat soluble
vitamins
OGT

408

306

510

94,979.86

95,052.71

34

25.5

42.5

95,013.25

95,019.32

Clinic visits*

1,244.56

933.42

1,244.56

94,905.16

95,016.28

902.27

94,935.72

95,016.28

1,189.764

94,910.05

95,016.28

18,989.63

93,659.88

96,372.68

Drug costs

Outpatient
902.27
676.70
visits*
Inpatient
1,189.764
892.32
stays*
Costs to treat adverse events
PE
15,191.71
11,393.78

Sensitivity analysis conducted at low (-25%) and high (+25%); * Sensitivity analysis conducted
at high (-10%) and low (-25%); AST: aspartate aminotransferase tes; ALT: alanine
aminotransferase test; PFT: pulmonary lung function test; OGT: oral glucose tolerance test;
PE: pulmonary exacerbations
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Table 26: Probabilities of medical events
Variable

Probability
base case
0.56

Probability
low
0.42

Probability
high
0.70

Base case

Low

High

1,244.56

933.42

Outpatient
visits
Inpatient stays

0.55

0.41

0.69

902.27

0.28

0.21

0.35

PE

0.31

0.24

0.38

Clinic visits

ICER at high

1,555.70

ICER at
low
94,905.16

672.57

1,131.89

94,934.25

95,098.29

1,189.764

892.32

1,487.21

94,910.05

95,122.51

15,191.71

11,761.32 18,622.10 93,791.14

96,241.42

Sensitivity analysis conducted at low (-25%) and high (+25%); PE: pulmonary exacerbations

95,127.41
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Figure 13: Tornado plot of one-way sensitivity analysis of cost effectiveness of
lumacaftor/ivacaftor

Variables

Sensitivity Analysis: CEA of lumacaftor/ivacaftor

70000

Drug cost
Standard therapy
Pulmonary exacerbations
Prob of pulmonary exacerbations
Prob of Clinic visits
Prob of inpatient stays
Prob of outpatient visits
Sputum culture
Clinic visits*
Inpatient stays*
Outpatient Visits*
Fat soluble vitamins
PFT’S
ALT
AST
Bilirubin
OGT
Flu shot
75000

80000

85000

90000

95000

100000 105000 110000 115000 120000

ICER
ICER at +25%

ICER at -25%

Sensitivity analysis conducted at low (-25%) and high (+25%); * Sensitivity analysis conducted
at high (-10%) and low (-25%); AST: aspartate aminotransferase test; ALT: alanine
aminotransferase test; PFT: pulmonary lung function test; OGT: oral glucose.
The PTMPM cost of lumacaftor/ivacaftor was not affected by varying the cost of other variables
and probabilities of occurrence of medical events. These results suggested that the baseline
budget impact model was robust to changes in most of the input parameters except, drug cost,
cost to treat and probability of pulmonary exacerbations.
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Tables 27 and 28 present results of sensitivity analysis of standard therapy alone. Tables 29 and
30 present results of sensitivity analysis post inclusion of lumacaftor/ivacaftor on the formulary
with preexisting standard therapy. Figure 14 presents the tornado plot of one way-sensitivity
analysis of budget impact of lumacaftor/ivacaftor. Increased (high) and decreased (low) input
ranges were plotted to determine the effect of different variables on the PTMPM. The results
suggest that even after varying the data input ranges, lumacaftor/ivacaftor therapy was stable to
most of the variables except for the cost of drug and pulmonary exacerbation. Refer Appendices
Table 37 for impact of variables on PTMPM cost.
Sensitivity analysis of standard therapy
Table 27: Costs
Variable

Base case

Low

High

PTMPM at
low

PTMPM at
high

89,742.40

67,306.80

112,178.00

6.7301

5.6833

Sputum culture

633.6

475.2

792

6.2104

6.2030

PFT’S

73.04

54.78

91.3

6.20716

6.2063

Flu shot

24

18

30

6.2069

6.2066

Fat soluble
vitamins
OGT

408

306

510

6.2091

6.2044

34

25.5

42.5

6.2069

6.2065

Clinic visits

1,382.25

1,037.13

1,728.56

6.2148

6.1987

Outpatient visits

1,002.53

751.89

1,253.16

6.2126

6.2009

Drug costs
Standard therapy
Monitoring costs
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Inpatient stays

1,321.96

991.47

1,652.45

6.2144

6.1990

14,334.11

23,890.17

6.3182

6.0953

Cost to treat adverse events
PE

19,112.14

Sensitivity analysis conducted at low (-25%) and high (+25%); PTMPM: per treated member
per month; OGT: oral glucose tolerance test.
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Table 28: Probabilities of medical events
Variable

Probability
Base case

Probability
low

Probability
high

Base case

Low

High
1,728.25

PTMPM
at
low
6.2148

PTMPM
at
high
6.1987

Clinic visits

0.56

0.42

0.70

1,382.25

1,036.95

Outpatient
visits
Inpatient
stays
PE

0.55

0.41

0.69

1,002.53

747.33

1,257.71

6.2127

6.2008

0.28

0.21

0.35

1,321.96

991.47

1,652.45

6.2144

6.1990

0.39

0.30

0.48

19,112.14

14,701.66

23,522.65

6.3096

6.1038
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Sensitivity analysis conducted at low (-25%) and high (+25%); PTMPM: per treated member per month; PE: pulmonary
exacerbations

Sensitivity analysis of lumacaftor/ivacaftor post inclusion of lumacaftor/ivacaftor on the
formulary with preexisting standard therapy
Table 29: Cost of medications
Variable

Base case

Low

High

PTMPM at
low

PTMPM at
high

Drug costs
Lumacaftor/ivacaftor

359,915.17

269,936.38

449,893.96

4.1076

8.3059

Monitoring costs
AST
ALT

56
56

42
42

70
70

6.2064
6.2064

6.2070
6.2070

Bilirubin

52

39

65

6.2064

6.2070

Sputum culture

633.6

475.2

792

6.2030

6.2104

PFT’S

73.04

54.78

91.3

6.2063

6.2071

Flu shot

24

18

30

6.2066

6.2069

Fat soluble vitamins

408

306

510

6.2043

6.2091

OGT

34

25.5

42.5

6.2065

6.2069

Clinic visits*

1,244.56

933.42

1,244.56

6.1995

6.2067

Outpatient visits*

902.27

676.70

902.27

6.2015

6.2067

Inpatient stays *

1,189.76

892.32

1,189.76

6.1998

6.2067

11,393.79

18,989.63

6.1181

6.2953

Cost to treat adverse events
PE
15,191.71

Sensitivity analysis conducted at low (-25%) and high (+25%), PTMPM: per treated member per
month; * Sensitivity analysis conducted at high (-10%) and low (-25%); AST: aspartate
aminotransferase test; ALT: alanine aminotransferase test; PFT: pulmonary lung function test;
OGT: oral glucose tolerance test; PE: pulmonary exacerbations
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Table 30: Probabilities of medical events
Variable

Probability Probability Probability Base case
Base case
low
high

Low

High
1,555.70

PTMPM
at
low
6.1995

PTMPM
at
high
6.2140

Clinic visits

0.56

0.42

0.70

1,244.56

933.42

Outpatient visits

0.55

0.41

0.69

902.27

672.57

1,131.89

6.2014

6.2121

Inpatient stays

0.28

0.21

0.35

1,189.76

892.32

1,487.21

6.1998

6.2137

PE

0.31

0.23

0.38

15,191.71

11,271.27 18,622.10 6.1153

6.2868
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Sensitivity analysis conducted at low (-25%) and high (+25%); PTMPM: per treated member per month; PE: pulmonary
exacerbations

Figure 14: Tornado plot of one-way sensitivity analysis of budget impact of
lumacaftor/ivacaftor

Sensitivity analysis: BIA of lumacaftor/ivacaftor
Drug costs
Pulmonary exacerbations
Prob of pulmonary exacerbations
Prob of clinic visits
Prob of inpatient stays
Prob of outpatient visits
Sputum culture

Variables

Clinic visits*
Inpatient stays *
Outpatient visits*
Fat soluble vitamins
PFT’S
ALT
AST
Bilirubin
OGT

Flu shot
4.0000

4.5000

5.0000

5.5000

6.0000

6.5000

7.0000

7.5000

8.0000

8.5000

PTMPM

PTMPM cost at +25% (high)

PTMPM cost at -25% (low)

Sensitivity analysis conducted at low (-25%) and high (+25%); * Sensitivity analysis conducted
at high (-10%) and low (-25%); AST: aspartate aminotransferase test; ALT: alanine
aminotransferase test; PFT: pulmonary lung function test; OGT: oral glucose tolerance test;
prob: probability.
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CHAPTER FIVE: DISCUSSION

This chapter provides the study findings, draws conclusions, presents study implications, lists
limitations of the study and provides recommendations for future research.

PART 1: BURDEN OF ILLNESS IN CYSTIC FIBROSIS
CF is a rare disease with a prevalence of 0.0089% in the US population. However, the economic
burden is substantial. Very few studies have reported burden of illness and CF healthcare
resource utilization. Most of the studies in the literature were conducted in early 2000s. 29,30 The
results indicate that CF-related medications and hospitalizations account for majority of the total
CF care costs. Given the lack of recent data on the economic burden of the disease due to
utilization of various medical services such as outpatient visits, emergency visits, office visits,
home health, prescription medications and hospital inpatient stays across the time, the present
burden of illness study was conceptualized to provide estimates of OOP and total economic
impact of CF. The burden of illness studies not only provide in depth estimates of utilization,
OOP and cumulative expenditures of various medical services, but quantify the economic impact
of CF on the entire US population. The objective of this part of the study was to estimate the
burden of illness due to CF using MEPS database using weighted estimates from a nationally
representative sample.
Specific research questions were to describe the demographics, clinical characteristics, resource
utilization of CF patients and to estimate the incremental cost burden in CF patients over control
population.
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Conclusion for part 1
Since CF is a rare condition, data was extracted from multiple years of MEPS. To check the
representativeness of the study sample, the demographics were compared to those identified in a
2015 Patient Registry Report. The analysis of 2010-2014 MEPS data identified a total of 109 CF
cases, out of which 78 (71.5%) were adults (≥18 years). However, the proportion of adults in the
sample was higher than that of CF population reported in Patient Registry which ranged from
38.7% to 51.6% from 2000 to 2015. The sample identified from the present study was much
older than that reported in the Patient Registry (Refer Appendices Table 32). The most common
gender and ethnicities affected by the disease were females, Whites followed by Hispanics. This
finding was contrary to CF Patient Registry Report as it reported majority of the CF patients to
be males (51.6%). A study by Harness-Brumley et al., (2014) presented an overview of gender
differences in outcomes of patients with CF. Using a retrospective cohort analysis of US CF
Foundation Patient Registry over a 13-year period, the authors reported that males were more
likely to be affected by CF than females. 134 However, unlike other X-linked disease genetic
conditions, CF occurs equally in men and women as it is an autosomal recessive disorder and
hence the genetic mutation for CF is not impacted by gender. 135 The severity of symptoms
related to CF, however, does vary in men and women. According to an argument made by CF
researchers, women with CF have more difficulty in growing and face more lung-related
problems compared to men because of the early-onset of lung infections and difficulty to
maintain healthy weight after puberty. 135 Due to these more severe symptoms, women with CF
have shorter life expectancies than men. It is estimated that men with CF live four to five years
longer than women with CF. Moreover, under the age of 20, girls have a 60% higher chance of
dying due to CF complications compared to males. Thus, the prevalence of male adults with CF
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is greater than the prevalence of female adults with CF. 135 A study conducted by Chatterjee et
al., utilizing 2003-2013 data from National Inpatient Sample (NIS) of HealthCare Cost and
Utilization Project (HCUP) reported that the percentage of hospital discharges were higher in
females than in males indicating severity of disease, worsening of symptoms, and need for
hospitalization in women. 42 This comparison of study sample with real world data highlights
challenges of using a public health care database for analysis. But, it is important to note that
Patient Registry does not provide expenditure information. The nature of data collection also
plays an important role as Patient Registry data is provided by CF foundation by surveying a
sample population referred by physicians whereas public healthcare databases avoid selection
bias by surveying a random and a representative sample. Hence, it is still possible to use public
healthcare databases to conduct analysis using a right methodology which was possible through
this study.
Only a minor proportion (around 1%) of the sample in the present study was uninsured
indicating the importance for insurance to cover and reimburse high expenses due to CF care and
economic burden of the disease on patients. It was also observed that, majority of the patient
population were covered under private insurances. This finding was similar to that of Patient
Registry Report. In 2015, 59.5% of total CF patients reported in the Registry had private
insurance, 9.6% had Medicare (covered around 20 to 40 percent of adults aged 30 to 65 years.
Individuals under age 65 who received Medicare met the federal criteria for disability), 44.8%
had Medicaid (including 57% of children under age 10 years), 2.4% had Tricare or other military
heath plan and only 0.7% had no insurance. The majority of people with CF who were age 18 to
25 years received health insurance through their parent’s plan. As insurance coverage reflected
coverage at any point during the year, these categories were not mutually exclusive. 21
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The most common comorbid conditions among adults identified from the present study were
high blood pressure, high cholesterol, and arthritis. A study using 2012 Kid’s Inpatient Database
(N=10,258 CF-related hospital discharges) and 2012 NIS (N=3,142 CF-related hospital
discharges) of HCUP data reported chronic obstructive pulmonary disease (30%), weight loss
and uncomplicated diabetes (20%), depression and electrolyte imbalance (8%) as frequently
occurring comorbidities among children (<18 years). Among adults (≥ 18 years), the most
common comorbid conditions were uncomplicated diabetes (31%), chronic obstructive
pulmonary disease (30%), weight loss (26%), fluid and electrolyte disorder (16%) and
depression (15%). 136,137 However, recent studies and CF treatment guidelines emphasized the
need to screen and treat for depression and anxiety, which are the most common comorbid
conditions occurring with CF resulting in poor quality of life. Evidence also suggests that
depression has negative effects on treatment adherence, family functioning, and health-related
quality of life. Since, MEPS data captured information related to specific comorbid conditions, it
was not possible to identify the prevalence of these comorbidities, which are considered
significant risk factors in the management of CF. 138
Analyses of the resource utilization in CF indicated that medical event expenditures were highest
for prescription medications followed by office visits. Total unweighted cumulative expenditure
for all the medical events across five years was $455,539.70 of which, total unweighted OOP
cost was $31,828.58. The estimated average unweighted cumulative expenditure was $770 for
office visits, $1,882 for prescription medications, $3,269 for outpatient visits, $13,031 for
inpatient stays and $566 for emergency visits. A study conducted by O’Sullivan et al., utilizing
claims data from 2002 to 2006 (N=1,064) to assess CF healthcare resource expenditure reported
mean cumulative expenditure for office visits as $625, prescription medications as $20,054,
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outpatient visits as $2,153, inpatient stays as $22,102 and emergency visits as $22. 31 Another
study by Sujit et al., analyzing commercial MarketScan claims database from 2005-2008
reported average annual cost due to prescription medications as $15,839, outpatient visits as
$8,397, inpatient stays as $8,885 and emergency room visits as $185. 41 There was a significant
difference in the prescription medications cost identified in the present study compared to these
published studies 22, 54 The difference could be attributable to the type of data as MEPS is a selfreported data, which is subjected to recall bias and result in over- or under-estimation of
households expenditure, whereas the two published studies was based on retrospective analysis
of claims databases which are more accurate compared to self-reported data as they are based on
actual resource utilization data. Secondly, the prescription medication costs may vary with the
type of existing comorbid conditions. MEPS data is limited to fewer comorbid conditions, which
may have accounted for lesser prescription medication cost. Third, the study conducted by
O’Sullivan et al., (2011) considered retrospective data of patients with pulmonary infections
(severe lung disease) whereas Sujit et al., (2012) study considered data of patients pre- and postpseudomonas aeruginosa infection which might be accountable higher costs due to prescription
medications.31, 41
Using estimates from the present study, the national annual direct medical expenditure associated
with CF care in the US was estimated at $6,691,134,764 across five years of which OOP
estimates were $615,098,138. Based on these estimates, the average annual cost of CF care in the
US was around $44,600 which is around $47,276 in 2016 dollars. The study conducted by
O’Sullivan et al., reported a total annual CF-related healthcare costs of $29,000 (in 2006 dollars)
which is around $40,600 in 2016 dollars and Sujit et al., reported the cost at $33,305 (in 2006
dollars) which is around $46,627 in 2016 dollars. The expenditure identified from our study was
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similar to the other studies when inflated to 2016. But, the difference in expenditure at different
time points may be due to increasing healthcare costs with advancement of technology and
increased access to resources and also because of the self-reported nature of MEPS data. 41
Total cumulative expenditure across five years in the MEPS data was highest for prescription
medications followed by inpatient stays, whereas total OOP expenditure was highest for
prescription medications followed by office visits. This could be due to the fact that, the inpatient
stays are generally covered by insurance making the OOP expenditure minimal. Among the
prescription medications, drugs used to treat diabetes, metabolic problems, pancreatic
insufficiency, respiratory agents and immune suppressants were most commonly utilized as they
are mostly used to treat CF-related complications. Highest cumulative expenditure was
accounted by antibiotics, respiratory agents, pancreatic agents and immunological agents.
The results of incremental cost burden analysis, after adjusting for covariates, reported that the
mean cumulative expenditure was $13,990 in children with CF and $3,231.27 in children without
CF whereas $16,975.80 in adults with CF it was and $8,859.87 in adults without CF. The
findings of the present study indicate that there was a significant cost burden of CF on cases
compared to controls. This cost was still an underestimate of the true cost because secondary
diagnosis and indirect costs associated with CF were not included in the analysis. These results
were different from a 2011 study utilizing 2004-2008 US administrative claims data which
reported an annual healthcare costs of CF to be $30,000, $57,000, and $215,000 for patients with
mild, moderate, and severe disease, respectively. The study also reported highest expenditure
among children of age group 10-14 years with CF severe disease with $343,900. Adults of age
group 40-44 years with mild CF disease had an expenditure of $15,600. 32 The differences in the
study estimates could be due to latest advances in the treatment including advanced screening
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techniques, maintenance therapy, novel CFTR modulator therapies, improved resources (>110
accredited CF care centers nationwide) which account for high treatment costs in CF. 139 Another
reason attributable to the differences in the study findings is the inability to assess disease
severity in MEPS database. The estimates obtained are representative of entire CF cases without
any differentiation of severity in different age groups whereas previous study findings were
based on disease severity among children and adults.

PART 2: PHARMACOECONOMIC EVALUATION OF
LUMACAFTOR/IVACAFTOR
CFTR modulator therapies have revolutionized the treatment paradigm for CF patients. With
changing healthcare policies and reimbursement patterns, managing healthcare costs is critical.
Insurance companies are increasingly demanding for health economic evidence to support their
formulary decisions. The CFTR modulator therapies have good clinical effectiveness including
increase in % FEV1 values, improvement in revised CF questionnaire (CFQR) scores, improved
body mass index (BMI) and reduction in pulmonary exacerbation events. These regimens,
therefore, have the potential to increase median life expectancy and delay the occurrence of
death. However, the annual cost of ivacaftor is estimated to be over $300,000 and
lumacaftor/ivacaftor is estimated to be around $270,000. Ivacaftor targets G551D CFTR
mutation whose prevalence is just around 4% in total CF population whereas
lumacaftor/ivacaftor targets F508del mutation, which has a prevalence of around 90% of total CF
population and around 45% with respect to homozygous F508del mutation. Hence, the market as
well as coverage for lumacaftor/ivacaftor is bigger compared to ivacaftor alone. Ivacaftor was
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initially approved in 2012 and has been shown to be cost effective based on published literature.
33,34

Lumacaftor/ivacaftor was approved in 2015 but was rejected by the Health Technology

Assessments like UK’s NICE and Ireland’s NCPE, stating poor cost effectiveness and significant
budget impact. 35,36 Little is known if lumacaftor/ivacaftor is affordable and cost effective in the
US healthcare system and there is no published economic evaluations reported. Thus, to
understand its value for money in the US healthcare system, an economic evaluation of
lumacaftor/ivacaftor is warranted. Specific research questions were to develop a cost
effectiveness and a budget impact model of lumacaftor/ivacaftor using MS Excel® to understand
the overall effectiveness and affordability of the drug from a payer perspective.

Conclusion for part 2
The CEA results reported that the cost of therapy per patient due to lumacaftor/ivacaftor was
$379,780.11 with an estimated ICER of $95,016.28 per FEV1% predicted. There are no
published studies which assessed cost effectiveness of lumacaftor/ivacaftor in the US. However,
a few international studies have been reported that assessed the ICER of lumacaftor/ivacaftor. In
2015, the NCPE of Ireland conducted the HTA of lumacaftor/ivacaftor and estimated an
incremental QALY gain of 2.45 with an incremental cost of €903,947 (US $1,017,103.08 in
2016 dollars) resulting in an ICER of €369,141/QALY (US $415,350.0 in 2016 dollars). The
model effects were mainly driven by mortality and the incremental life years gained were
estimated to be 2.47, resulting from a median increase in overall survival of 7.4 years. A oneway sensitivity analysis highlighted that the cost of lumacaftor/ivacaftor impacted the ICER in
the analysis. The study concluded that lumacaftor/ivacaftor was not cost effective for the
treatment of CF in patients 12 years and older who were homozygous for the F508del mutation
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in the CFTR gene and therefore, it was not recommended for reimbursement in Ireland. 36 The
major differences between this study and NCPE were the source of data and choice of clinical
end points. The NCPE HTA was sponsored and the model inputs were provided by the
manufacturer of lumacaftor/ivacaftor whereas this study was conducted as a part of academic
research and model inputs were taken from public sources like Physician Fee Schedule of
Centers for Medicare and Medicaid (CMS), Redbook or published literature. The NCPE HTA
used QALY as clinical outcome whereas this study utilized FEV1% predicted. QALY is
preferred in a cost utility analysis (CUA) or a CEA when utilities for each transition state and
long term clinical effectiveness is known. But this study used a more appropriate measure i.e.
FEV1% predicted because the long term clinical effectiveness and the transition states possible
after treatment initiation were not known at the time this study was conducted.
In 2016, the NICE in the UK issued a draft guidance against recommending
lumacaftor/ivacaftor for treating CF. The guidance reported an annual treatment cost of €104,000
(US $118,560 in 2016 dollars) per patient due to lumacaftor/ivacaftor. In 2016, the Scottish
Medicines Consortium also issued a guidance which did not recommend lumacaftor/ivacaftor. 35
In the US, the CEA threshold, traditionally ranged from US $50,000 per QALY gained. This
threshold has recently been updated to $100,000 or $150,000 per QALY gained to account for
the increased willingness to pay which was $50,000 to $100,000 per QALY 2 decades ago. 140,141
Although the ICER of lumacaftor/ivacaftor calculated in the present study was above the initial
threshold of US $50,000, it is still within the debatable range of formulary consideration given
the nature of the disease. Ivacaftor and lumacaftor/ivacaftor represent a paradigm shift in the
treatment of CF and clinical trial data have provided evidence of better outcomes in this
population. These CFTR modulator therapies are the only available disease modifying therapies
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which have the potential to increase the median life expectancy in CF patients. The current
median predicted survival age is close to 40, which is a dramatic improvement from the 1950’s,
when a child with CF rarely lived long enough to attend elementary school. 3 The possibility of
increased life expectancy with newer treatments may be a justification for accepting the high
ICER thresholds. The uncertainty analyses also suggest that this conclusion is relatively modest
to the model assumptions over a large range of inputs. However, the ICER of
lumacaftor/ivacaftor was most likely to be influenced by change in cost of lumacaftor/ivacaftor,
standard therapy and cost to treat pulmonary exacerbations.
The results of BIA reported an annual cost of $113,734.52 due to standard therapy and
$379,780.11 after the inclusion of lumacaftor/ivacaftor on the formulary with existing standard
therapy. Hence, the annual total budget impact due to inclusion of the drug on the formulary was
$266,045.59 resulting in a PMPM cost of $0.022 (based on a one million hypothetical plan
population) and a PTMPM cost of $6.2067 based on a target population of 3,572. One-way
sensitivity analysis showed that the PTMPM cost of lumacaftor/ivacaftor was most likely to be
influenced by change in cost of lumacaftor/ivacaftor, cost to treat pulmonary exacerbations and
probability of occurrence of pulmonary exacerbations. The PTMPM cost of lumacaftor/ivacaftor
was not affected by varying the cost of other variables and probabilities of occurrence of medical
events. These results suggested that the baseline budget impact model was robust to changes in
most of the input parameters except drug cost, cost to treat, and probability of pulmonary
exacerbations. There were no previous studies that assessed the affordability of
lumacaftor/ivacaftor in the US. However, the BIA study in Ireland, assessed an annual cost of
lumacaftor/ivacaftor at €158,306 (US $178,122.74 in 2016 dollars) or €159,050 (US
$178,959.87 in 2016 dollars) including the patient care fee for a target population of 505. The

126

manufacturer (Vertex Pharmaceuticals) estimated the 5-year gross budget impact of
lumacaftor/ivacaftor at €352,281,736 (US $396,380,363.71 in 2016 dollars). The study estimate
of the 5-year budget impact was €391,892,681 (US $440,949,806.80 in 2016 dollars). In
conclusion, they reported that the budget impact due to lumacaftor/ivacaftor was significantly
higher. 36 The Institute for Clinical and Economic Review published an estimated annual
potential budget impact threshold of $904 million for each new molecular entity for the year
2016. 142 But, decisions regarding BIA’s are made purely by the payers and, assessing whether a
PMPM and a PTMPM cost falls within a US national threshold is difficult. However, based on
our results, a 5-year gross budget impact of lumacaftor/ivacaftor was estimated at a PMPM cost
of $1,320,000 and a PTMPM cost of $1,330,219.94.

IMPLICATIONS OF STUDY FINDINGS
The present study was undertaken to assess the burden of illness due to CF and to evaluate the
overall effectiveness and affordability of lumacaftor/ivacaftor in the treatment of CF. The present
study improved upon some previous national estimates of CF and estimated the major domains
of healthcare utilization. The study findings are important for several reasons. Increased
coverage for uninsured population in healthcare system coupled with an increase in aging
population and increase in the prevalence of CF could potentially result in increased healthcare
recourse utilization. Thus, there is a need to introduce strategies at the primary care level, which
will not only decrease the burden of CF on the healthcare system but also reduce the overall
costs associated with the disease. Strategies like disease screening and increased health literacy
will be helpful in decreasing the overall disease burden by early detection and appropriate
treatment in rare disease like CF and mucopolysaccharidosis. 143-145 As discussed earlier,
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screening techniques such as the use of new born screening, prenatal testing and genetic testing
can be helpful in controlling the increase in disease severity in a timely manner. Currently, there
are increased cases of CF among individuals less than 18 years of age. Hence, there is a need to
implement programs like health awareness among children about the risk factors for CF. A study
on CF patient experiences reported lack of time, forgetfulness and too many medications as
barriers to treatment. More education, avoiding hospitalization were identified as motivators of
treatment. 145 For reducing resource utilization among elderly individuals suffering from chronic
conditions like CF, improved adherence to treatment with home health model could be
implemented, that will help in decreasing the emergency room and inpatient facility expenses,
and would also provide better care to the individuals. 145

Implications to the payers
Although the ICER of lumacaftor/ivacaftor is still debatable for reimbursements, it has the
potential to delay disease progression and offset costs due to events like lung transplantation
which occur at later stages of CF disease thus leading to life time cost savings in patients with
homozygous F508 del mutation. Managed care organizations may not see short-term cost
savings by covering lumacaftor/ivacaftor, however, the long-term benefit to payers and patients
must be considered before making formulary and coverage decisions. This study will help the
managed care organizations and payers such as Medicare/Medicaid in understanding the
increased burden of CF. The systematic assessment of CF and their associated incremental costs
to the society is essential in increasing the awareness of decision makers to implement
intervention strategies that are effective in lowering the disease incidence and in reducing the
overall cost of disease management. The implementation of disease management programs like
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home health, screening for early disease detection and the use of cost-effective treatments will
help payers control the rising costs of CF, including the cost of CF-related prescription
medications.

Implications to the prescribers
The current treatment guidelines indicate the use of lumacaftor/ivacaftor for CF patients aged 6
years and above with homozygous F508 del mutation of CFTR. While the regimen is shown to
be clinically effective resulting in positive absolute change in FEV1% predicted values from
baseline values, the results of published clinical trials also reported high rates of treatment
discontinuation (4.6%) compared to placebo (1.6%) attributable to adverse events (pulmonary
exacerbations). Therefore, prescribers should value treatment guidelines along with their own
clinical judgment while making treatment decisions for their patients.

Implications to patients
The overall discontinuation rates were higher in lumacaftor/ivacaftor group compared to placebo
group and of the patients that discontinued treatment, the primary reason reported were adverse
events which was pulmonary exacerbations predominantly. The current formulary matrix
indicates lumacaftor/ivacaftor to be a specialty tier with many commercial insurance companies
and pharmacy business managers not including the drug on the formulary (Refer Table 31). Few
payers cover lumacaftor/ivacaftor for a six month or one-year time frame with a prior
authorization. 146-148
Only 35-40% of CF population are covered under Medicaid and lumacaftor/ivacaftor is covered
under Medicare Part D with a typical copay range of $6,014 - $24,057. 149
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Table 31: Market access matrix of lumacaftor/ivacaftor
Payer
Medicare Part D
UHC
Humana
Cigna
Commercial
UHC
Anthem
Aetna
PBM
Express scripts
Optum
CVS caremark

Lumacaftor/ivacaftor*
Specialty tier (unique and/or very high cost drug)
Specialty tier
Not covered
Not covered
Not covered
Specialty drug (very high cost drug)
Not covered
Not covered
Specialty drug and it requires prior authorization

Top 3 Medicare beneficiaries, commercial insurance companies and pharmacy business
managements considered (based on 2017 coverage policies).
*Redbook WAC of lumacaftor/ivacaftor, WAC last updated on July 1st, 2017.
30 days: $19,923.08 (2015), annual: $270,172.77 (inflated to 2016)
30 days: $20,919.23 (2017, annual: $272,577.56 (2017)
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As the prevalence of CF is more in children and young adults, Medicare might not protect a large
proportion of CF patients except those who are 65 years and above or with end stage renal
disease and disabilities. However with an average monthly copay of $1,252.94, in those who are
covered under Medicare, patients reach the donut hole (coverage gap of $3,310 in 2016) in the
third month which will make the patients responsible for major part of their prescription
medications costs. Once, the patients reach post donut hole (also called catastrophic coverage,
$4,850 in 2016) stage, Medicare will cover most of the drug costs. 37
Another major implication to patients is that the manufacturer cannot provide direct patient
assistance program when they are covered under Medicare part D. Hence, the manufacturers
provide indirect assistance by donating to disease foundations. In 2015, 30.9% of a total 28,983
CF patient population participated in patient assistance program provided by CF Foundation. 21
However, the Department of Health and Human Services (HHS) keeps a check on these patient
assistance programs to restrict indirect incentivization of patients by manufacturers for using
their products. Patients should consider these implications while discussing concerns with their
payers and seek provider’s regular help for side effects monitoring, education or counseling to
understand their regimen, possible side effects due to lumacaftor/ivacaftor and make decisions
accordingly.

LIMITATIONS OF THE STUDY
Both parts of the study have some limitations and these are discussed in the following section.
These limitations need to be considered before deriving inferences from the reported results.
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Limitations of burden of illness study
The limitations associated with any retrospective database are applicable to this study. Some of
these limitations include retrospective nature of the data, whose quality may be limited by
systematic or recorder bias, data coding-recoding errors, incomplete data, data quality, and
confounding factors. MEPS database provides self-reported information collected from a sample
of families and individuals in selected communities across the US, drawn from a nationally
representative subsample of households that participated in the prior year's National Health
Interview Survey (conducted by the National Center for Health Statistics). Individuals with CF
were identified based on the medical conditions they reported. This could potentially overestimate or under-estimate disease prevalence. Similarly, there was a possibility of overestimating or under estimating the expenditures. Also, self-reported data can possibly introduce
recall bias as the data is based on recollecting the time when the event occurred. Second, the
analysis only included direct medical expenses. Indirect cost such as loss of productivity
transportation expenses, lost wages among family members, caregiver burden, were not included
in the estimation of the overall expenditures calculation. Third, the study included only patients
with the primary diagnosis of CF, since MEPS does not provide secondary diagnosis. Fourth,
MEPS does not provide any data on disease severity and disease history. These are important
covariates in predicting the total healthcare expenditures. Since, the CF sample identified from
MEPS database reported other existing comorbid conditions, it was not possible to identify
disease severity in CF cases based on expenditures, frequency of medical events. Fifth, MEPS
captures information on fewer comorbid conditions such as cardiovascular diseases, cancer,
diabetes, arthritis, and asthma. In children, the only comorbidity that was captured was asthma.
Information related to other important comorbidities associated with CF such as gastro intestinal
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disorders, pancreatic disorders, problems related to fertility and reproduction were not reported.
Finally, as lumacaftor/ivacaftor was approved in 2015 by US FDA and the data used for the
present study was from 2010-2014, it was not possible to capture information about the impact of
CFTR modulator therapies on healthcare resource utilization including prescription medications.

Limitations of the pharmacoeconomic evaluation study
Although, the present study is one of the first studies to conduct pharmacoeconomic evaluation
of lumacaftor/ivacaftor, there were some limitations. First, there were no existing comparator
drugs as lumacaftor/ivacaftor is indicated to CF patients with homozygous F508 del mutations.
Hence, the evaluations involved comparisons against placebo or standard therapy. Second, the
standard therapy available in the market consisted of maintenance therapies and the present study
was restricted to the use of standard therapy consisting of pulmonary medications mentioned in
the published clinical trials of lumacaftor/ivacaftor which did not include drugs used to treat CF
complications.
Third, cost inputs and probabilities of events used in the models were obtained from multiple
sources including Medicare reimbursements, healthcare blue book and published literature.
Although one-way sensitivity analyses were conducted to vary input ranges, the result estimates
of any modeling study need to be treated with some degree of caution. Fourth, it was not possible
to develop dynamic models consisting of transition state probabilities as the drug was not
approved until 2015 and long-term data were unavailable. Lastly, the analyses involved certain
assumptions such as 100% adherence to treatment and unchanged prevalence of CF in 2015 and
2016 which may differ from real world scenarios.
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RECOMMENDATIONS FOR FUTURE RESEARCH
All the evidence generated from the present study indicate that there is a significant economic
burden due to CF and lumacaftor/ivacaftor has reasonable value for money. Although the present
study identified varied prevalence of CF among ethnicities, there are no studies that explain the
reasons behind this disparity. Future studies should explore reasons behind disparities in
prevalence associated with demographic characteristics. There is also a need to understand cost
effectiveness and affordability of the drug over a lifetime period using dynamic Markov models
in the US. Since the data inputs used in this study were from published clinical trials and
literature, real-world drug effectiveness should be assessed using data from large- claims
databases that have a robust sample size. Future research should also capture information on
indirect costs using societal perspective to get more comprehensive picture of the overall
effectiveness of the drug, especially on caregivers. Another major area for future research would
be to include humanistic outcomes by conducting a qualitative research like focus groups,
interviews with CF patients to understand their health status, quality of life, satisfaction, barriers
to treatment and other important factors.
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APPENDICES
Table 32: Demographics of CF sample identified from MEPS database and Patient
Registry report
Cases (N= 109)
Individual
characteristics (Children= 31)
Age

Gender

Mean: 38.2 ± 25.32
years
Median: 39 years
Range: 0-82 years
Male: 39 (35.77%)
Female: 70 (64.22%)

Controls
(N= 85,521)
(Children= 24,650)
Mean: 35.75 ± 23.31years
Median: 34 years
Range: 0- 85 years

Patient Registry
(N= 28,983)
(Children= 14,027)
Mean: 20.9 years
Median: 18.6 years

Male: 39,433 (46.11%)
Female: 46,088 (53.89%)

Males:
14,955(51.6%)
Female:
14,027(48.4%)
White: 27,186
(93.8%) *
Black: 1,333 (4.6%) *
Hispanic: 2,463
(8.5%) *
Others: 956 (3.3%) *

Race

White: 71 (65.14%)
Black: 16 (14.68%)
Hispanic: 17 (15.60%)
Asian: 2 (1.83%)
Others: 3 (2.75%)

White: 244,96 (28.64%)
Black: 11,903 (13.92%)
Hispanic: 16,932
(19.80%)
Asian: 3,727 (4.35%)
Others: 1,971(2.30%)
Missing: 26,492 (30.98%)

Household
income

Mean: $59,903.78
(95% CI: $49,467.19,
$70,340.37)
Married: 36 (32.03%)
Not married: 44
(40.36%)
Underage (<16 years):
29 (26.60%)

Mean: $59,549.47
(95% C.I: 59,171.39,
59,927.55)
Married: 8,977 (10.50%)
Not married: 10,360
(12.11%)
Underage (<16 years):
5,655 (6.61%)
Missing: 60,529 (70.77%)
Any private: 46,086
(53.89%)
Public: 28,671 (33.52%)
Uninsured: 10,764
(12.59%)

Marital status

Insurance
Coverage

Any private: 73
(66.97%)
Public Only: 35
(32.11%)
Uninsured: 1 (0.92%)
*
Not mutually exclusive
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Married: 12,028
(41.5%)
Not married: 16,955
(58.5%)
Any private: 17,245
(59.5%) *
Public: (56.8%) *
Uninsured: 202
(0.7%)

Table 33: Resource utilization in cystic fibrosis cases from 2010-2014
Medical
event
Office
visit

Type of
expenditure

2010
2011
2012
2013
2014
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2010-2014
Home health
2010
2013
2014
2010-2014

Prescription
medications
2010
2011

Unweighted ($)

Weighted ($)

Mean (95% CI)

Total

Mean (95% CI)

Total

236.00 (104.79-367.21)
20.20 (0-46.02)
866.90 (0-2,215.14)
64.39 (0-137.64)

Standard
error
of mean
60.22
12.03
596.00
32.38

Cumulative
OOP
Cumulative
OOP

270.65 (132.28-409.01)
26.76 (0-60.56)
750.63 (0-1,683.13)
97.68 (0-203.58)

3,518.45
348.00
9,007.65
1,172.21

Cumulative
OOP
Cumulative
OOP
Cumulative
OOP
Cumulative
OOP

698.58 (142.64-1,254.53)
54.29 (19.36-89.23)
387.37 (188.77-585.97)
76.0 (0-154.56)
1,992.26 (0-4,441.19)
213.58 (0-445.55)
769.53 (342.21-1,196.85)
87.30 (43.25-131.33)

16,766.06
1,303.17
8,134.89
1,596.16
27,891.63
2,990.17
65,410.35
7,419.71

615.66 (137.91-1,093.42)
54.36 (25.08-83.63)
354.30 (180.27-528.33)
79.49 (4.86-154.12)
2,561.69 (0-6,608.70)
393.29 (73.30-713.28)
777.49 (194.80-1,360.18)
101.17 (39.38-162.97)

230.94
14.15
83.42
35.77
1,873.29
148.11
292.90
31.06

208,612,877
18,419,478
77,593,347
17,409,519
381,228,802
58,529,799
812,971,988
105,795,071

Cumulative
OOP
Cumulative
OOP
Cumulative
OOP
Cumulative

7,800
0
0
0
4,825 (0-18,306.28)
49.0 (0-671.60)
4,362.50 (0-9,681.97)

7,800
0
0
0
9,650.00
98.0
17,450.00

0
0
0
0
382.79
28.67
515.31

91,567,718
0
0
0
281,645,861
4,377,427
373,213,579

OOP

24.50 (0-102.46)

98.0

7,800
0
0
0
5,673.27 (809.36-10,537.18)
68.75 (0-160.00)
5,861.76 (4,221.797,501.73)
68.75 (0-160.00)

28.67

4,377,427

Cumulative
OOP
Cumulative
OOP

239.15 (9.12-469.17)
39.29 (0-84.19)
272.00 (0-589.52)
45.66 (3.80-87.53)

1,674.03
275.03
4,080.14
684.93

234.76 (56.76-412.76)
49.26 (0-101.58)
235.35 (0-512.42)
49.93 (12.25-87.62)

72.75
21.38
128.25
17.45

23,321,143
4,893,934
49,471,759
10,496,571

46,727,279
3,999,927
96,042,725
7,134,509

2012
2013
2014
2010-2014
Inpatient
stays
2010

2011
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2012

2013

2014

Cumulative
OOP
Cumulative
OOP
Cumulative
OOP
Cumulative

38,569.02
8,843.69
39,505.82
3,362.63
66,805.19
5,162.38
150,634.20

1,587.35 (0-3,994.60)
550.36 (0-1,550.89)
1,728.50 (0-4,439.82)
150.10 (0-357.42)
4,996.49 (0-12,183.55)
669.38 (0-1,751.49)
2,046.10 (143.38-3,948.82)

1,157.55
481.11
1,278.98
97.80
3,420.91
515.07
955.73

589,327,708
204,329,474
369,990,095
32,129,508
1,352,899,495
181,248,970
2,385,010,201

OOP

1,753.14 (0-3,566.72)
401.99 (0-1,079.77)
2,323.87 (0-6,091.51)
197.80 (0-489.56)
3,516.06 (0-7,996.85)
271.70 (0-658.58)
1,882.93 (538.493,227.37)
229.11(23.58-434.64)

18,328.66

371.56 (0-767.00)

198.63

433,098,457

Cumulative
For facility
For doctor
OOP
For facility
For doctor
Cumulative
For facility
For doctor
OOP
For facility
For doctor
Cumulative
For facility
For doctor
OOP
For facility
For doctor
Cumulative
For facility
For doctor
OOP
For facility
For doctor
Cumulative
For facility
For doctor
OOP

2,138.76
1,951.95
186.81
177.37
140.0
37.37
7,261.97 (0-45,359.80)
6,572.33 (0-35,907.53)
689.63 (0-9,452.28)
10.0 (0-137.062)
0
10.0 (0-137.062)
16,809.49 (0-72,631.18)
15,359.32 (0-65,129.10)
1,450.17 (0-7,548.02)
0
0
0
13,915.21
12,695.47 (0-56,559.63)
1,219.74 (0-4,640.38)
126.87 (0-442.15)
0
126.87 (0-442.15)
17,252.24 (0-53,992.87)
15,817.37 (0-43,093.46)
1,434.88 (0-10,899.41)
68.86 (0-877.42)

2,138.76
1,951.95
186.81
177.37
140.0
37.37
14,523.93
13,144.66
1,379.27
20.0
0
20
50,428.46
46,077.96
4,350.50
0
0
0
41,745.62
38,086.40
3,659.22
380.63
0
380.63
34,504.48
31,634.73
2,869.75
137.73

2,138.76
1,951.95
186.81
177.37
140.0
37.37
10,260
8,881.06
1,379.27
20.0
0
20.0
20,515 (0-80,647.01)
18,681 (0-72,136.65)
1,834.01 (0-8,541.53)
0
0
0
12,308 (0-57,114.65)
11,144 (0-52,969.18)
1,164.83 (0-4,185.71)
100.39 (0-451.58)
0
100.39 (0-451.58)
16,773 (0-52,505.56)
15,462 (0-41,989.29)
1,311.47 (0-10,516.27)
79.40 (0-865.77)

0
0
0
0
0
0
0
0
0
0
0
0
13,976
12,424
1,558.92
0
0
0
10,414
9,720.89
702.09
81.62
0
81.62
2,812.19
2,087.76
724.43
61.88

22,279,789
20,333,761
1,946,028
1,847,690
1,458,401
389,289
90,993,224
78,761,237
12,231,987
177,369
0
177,369
146,401,438
1,333,133,494
130,880,887
0
0
0
421,740,687
381,828,192
39,912,495
3,439,816
0
3,439,816
200,098,600
188,425
758,870
947,295

2010-2014

For facility
For doctor
Cumulative

27.10
110.63
143,341.25

15.79 (0-183.23)
63.61(0-682.53)
16,070 (0-32,402.03)

13.17
48.71
7,219.46

184,453,125
15,645,475
2,199,126,682

130,895.70

14,604 (0-29,252.61)

6,475.32

1,998,509,809

12,445.55

1,466.03 (0-3,179.34)

757.37

200,616,873

OOP
For facility
For doctor

13.55 (0-185.71)
55.31 (0-691.70)
13,031.02 (3,450.1122,611.93)
11,899.61 (3,216.6420,582.58)
1,131.41 (188.502,074.33)
65.06 (3.72-126.41)
15.19 (0-43.53)
49.87 (0-104.48)

715.73
167.10
548.63

46.85 (0-105.50)
12.03 (0-37.43)
34.82 (0-83.75)

25.92
11.22
21.62

6,412,171
1,646,826
4,765,344

Cumulative
For facility
For doctor
OOP
For facility
For doctor
Cumulative
For facility
For doctor
OOP
For facility
For doctor
Cumulative
For facility
For doctor
OOP
For facility
For doctor
Cumulative
For facility
For doctor
OOP
For facility
For doctor
Cumulative
For facility

220.57 (0-625.73)
173.02 (0-429.49)
47.55 (0-198.87)
52.89 (0-164.20)
52.89 (0-164.20)
0
3,243.37
2,904.30 (0-7,539.34)
339.06 (0-1098.05)
391.64 (0-1,441.36)
356.34 (0-1,345.73)
35.29 (0-102.07)
10,100.60 (0-34,318.27)
6,615.53 (0-22,362.89)
3,485.07 (0-11,957.40)
546.37 (0-1,947.20)
424.01 (0-1,485.69)
122.36 (0-462.08)
798.08 (0-2,738.80)
734.86 (0-2,486.78)
63.22 (0-252.11)
3.75 (0-15.68)
3.75 (0-15.68)
0
272.39 (0-790.85)
133.53 (0-443.37)

882.30
692.10
190.20
211.58
211.58
0
16,216.85
14,521.51
1,695.34
1,958.20
1,781.74
176.46
50,503.01
33,077.66
17,425.35
2,731.89
2,120.09
611.80
3,192.34
2,939.45
252.89
15.00
15.00
0
817.18
400.60

188.58 (0-470.43)
157.90 (0-334.63)
30.68 (0-142.24)
79.72 (0-210.29)
79.72 (0-210.29)
0
2,722.62 (0-7,796.45)
2,424.32 (0-6,826.50)
298.30 (0-1,054.00)
356.62 (0-1,374.31)
326.78 (0-1,280.82)
29.84 (0-97.30)
11,496 (0-37,895.52)
7,530.20 (0-24,685.22)
3,966.01 (0-13,212.89)
622.08 (0-2,156.07)
483.71 (0-1,643.05)
138.36 (0-513.70)
367.66 (0-1,125.86)
345.78 (0-1,031.52)
21.88 (0-94.69)
5.81 (0-21.29)
5.81 (0-21.29)
0
303.54 (0-904.73)
149.89 (0-513.05)

88.56
55.53
35.05
41.02
41.02
0
1,827.45
1,585.54
272.18
366.54
343.61
24.29
9,508.31
6,178.77
3,330.47
552.50
417.56
135.18
238.24
215.47
22.88
4.86
4.86
0
139.72
84.40

11,723,067
9,815,754
1,907,313
4,956,288
4,956,288
0
175,641,035
156,396,789
19,244,246
23,006,648
21,081,310
1,925,337
610,179,280
399,677,140
210,502,140
33,017,867
25,673,913
7,343,955
10,955,329
10,303,202
652,128
173,206
173,206
0
31,055,619
15,336,035

For facility
For doctor

Outpatient
visits
2010
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2011

2012

2013

2014

2010-2014

Emergency
visits
2011
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2012

2013

2014

2010-2014

For doctor
OOP
For facility
For doctor
Cumulative
For facility
For doctor
OOP
For facility
For doctor

138.86 (0-351.33)
19.66 (0-61.99)
9.66 (0-51.25)
10.00 (0-53.02)
3,268.98 (0-7,517.78)
2,360.78 (0-5,171.07)
908.19 (0-2,378.87)
226.32 (0-518.35)
189.13 (0-430.77)
37.19 (0-95.45)

416.58
59.00
29.00
30.0
71,917.52
51,937.16
19,980.36
4,979.17
4,160.91
818.26

153.64 (0-393.59)
23.31 (0-55.25)
10.22 (0-53.79)
13.09 (0-61.22)
2,481.51 (0-5,893.63)
1,756.38 (0-4,020.69)
725.12 (0-1,892.13)
186.07 (0-419.90)
155.05 (0-349.41)
31.01 (0-77.16)

55.76
7.42
10.12
11.18
1,640.74
1,088.81
561.16
112.44
93.46
22.19

15,719,585
2,385,643
1,045,615
1,340,029
848,785,772
600,760,361
248,025,411
63,645,296
53,035,975
10,609,321

Cumulative
For facility
For doctor
OOP
For facility
For doctor
Cumulative
For facility
For doctor
OOP
For facility
For doctor
Cumulative
For facility
For doctor
OOP
For facility
For doctor
Cumulative
For facility
For doctor
OOP
For facility
For doctor
Cumulative
For facility
For doctor

846.76 (0-3,231.29)
755.17 (0-3,065.69)
91.58 (0-184.66)
0
0
0
211.13 (0-615.89)
180.92 (160.02-201.82)
30.21 (0-414.06)
0
0
0
523.30 (0-1,781.31)
407.07 (0-1,808.16)
116.23 (0-260.09)
0
0
0
563.47 (0-1,755.42)
324.13 (0-1,074.67)
239.34 (0-700.93)
71.82 (0-222.74)
46.827 (0-133.26)
25.00 (0-104.56)
565.53 (157.57-973.49)
428.76 (69.26-788.25)
136.77 (25.72-247.81)

2,540.29
2,265.53
274.76
0
0
0
422.27
361.85
60.42
0
0
0
1,569.92
1,221.23
348.69
0
0
0
2,253.90
1,296.52
957.38
287.31
187.31
100.00
6,786.38
5,145.13
1,641.25

174.60
124.60
50.00
0
0
0
215.02 (0-613.75)
181.12 (160.53-201.71)
33.89 (0-412.03)
0
0
0
919.96 (0-1,915.10)
847.41 (0-1,958.76)
72.54 (0-188.78)
0
0
0
621.32 (0-2,006.53)
359.63 (0-1,220.25)
261.69 (0-798.78)
77.23 (0-248.57)
46.89 (0-137.41)
30.34 (0-120.40)
535.14 (57.518-1,012.76)
447.42 (0-915.91)
87.71 (1.34-174.08)

0
0
0
0
0
0
31.38
1.62
29.76
0
0
0
231.28
258.29
27.01
0
0
0
435.26
270.42
168.76
53.83
28.44
28.29
211.13
207.09
38.17

1,645,216
1,174,077
471,139
0
0
0
11,568,811
9,745,100
1,823,711
0
0
0
44,576,441
41,061,412
3,515,029
0
0
0
14,236,074
8,240,059
5,996,015
1,769,716
1,074,420
695,296
72,026,542
60,220,648
11,805,893

OOP
For facility
For doctor

23.94 (0-62.61)
15.60 (0-38.83)
8.33 (0-26.67)

287.31
187.31
100.0

13.14 (0-40.26)
7.98 (0-23.12)
5.16 (0-17.94)

11.98
6.69
5.64

1,769,716
1,074,420
695,296

OOP: out-of-pocket; CI: confidence interval; mean: mean costs for all the observations of a medical event in a year; total: sum of
costs for all the observations of a medical event in a year; out of pocket: expenditure paid directly by an individual; cumulative:
expenditure paid by an individual and by other sources like insurance; 95% CI was not available for events having only one
observation or more than one observation with expenditure available only for one observation; some of the events had negative
confidence intervals because of statistical calculations; for this study, negative values of confidence intervals were converted to 0 to
avoid misinterpretation of negative values as savings due to occurrence of medical event.
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Table 34: Cumulative expenditure of prescription medications (2010-2014)
Drug name
Respiratory agents
Creon
Aminoglycosides
Immunologic agents
Myfortic
AAA batteries
Selective
immunosuppressants
Xopenex
Spiriva
Oxycontin
Levocarnitin
Prevacid
Deplin 15
Metformin
Pataday
Hormones/hormone
modifiers
Lantus
Singulair
Bayer contor
Azithromycin
Niaspan
l-methylfola
Tramadol hcl
Phlexy-10
Clonidine
Epipen-jr
Minocycline
Warfarin
Dexamethason
Mycophenolat
Albuterol
Pot citrate
Pancrelipase
Precisn xtra
Apidra

Frequency
N (%)
43 (7.80%)
20 (3.60%)
2 (0.40%)
5 (0.90%)
7 (1.30%)
10 (1.80%)
4 (0.70%)

Mean cumulative
expenditure (S.D) $
3,213.38 (253.06)
758.51 (899.34)
6,653.6 (0)
1,235.3 (0)
627.56 (115.62)
432.67 (0)
956.15 (0)

Total cumulative
expenditure $
78,316.47
15,170.16
13,307.2
6,176.5
4,392.94
4,326.7
3,824.6

4 (0.70%)
3 (0.50%)
5 (0.90%)
44 (7.90%)
8 (1.40%)
7 (1.30%)
52 (9.40%)
7 (1.30%)
13 (2.30%)

820.4 (0)
741.12 (0)
437.47 (0)
42.21 (12.02)
194.06 (9.52)
115.23 (0)
15.51 (17.29)
114.51 (0.42)
59.16 (9.13)

3,281.6
2,223.36
2,187.35
1,857.02
1,552.48
806.61
806.33
801.6
769.05

3 (0.50%)
5 (0.90%)
5 (0.90%)
4 (0.70%)
4 (0.70%)
5 (0.90%)
6 (1.10%)
4 (0.70%)
10 (1.80%)
1 (0.20%)
5 (0.90%)
11 (2.00%)
12 (2.20%)
5 (0.90%)
8 (1.40%)
9 (1.60%)
1 (0.20%)
2 (0.40%)
2 (0.40%)

225.53 (9.95)
128.42 (0)
110.13 (5.68)
113.88 (73.94)
111.42 (3.04)
89 (10.51)
71.37 (41.43)
93.75 (0)
33.92 (39.74)
317.33 (-)
59.38 (57.11)
25.81 (7.23)
23.32 (4.12)
55.01 (5.26)
32.49 (12.28)
28.41 (17.46)
249.78 (-)
119.37 (0)
117.26 (150.05)

676.58
642.1
550.66
455.5
445.68
444.95
428.2
375
339.15
317.33
296.92
283.9
279.88
275.06
259.92
255.65
249.78
238.74
234.52
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Gabapentin
Methotrexate
Flovent HFA
Pentoxifylli
Neurontin
Prednisone

4 (0.70%)
4 (0.70%)
1 (0.20%)
8 (1.40%)
2 (0.40%)
21 (3.80%)

54.99 (32.89)
50.54 (0)
188.91 (-)
22.57 (10.36)
75.55 (0)

Adipex-p
Methocarbam
Folgard RX
Allopurinol
Danazol
Lansoprazole
Qvar
Cephalexin
Hyoscyamine
Folbic
Levothyroxin
Polyeth Glyc
Pravastatin
Optichamber
Cyanocobalam
Cyproheptad
Omega-3 fatty acids cap
1000 mg
Test strip
Tricor
Mag-ox 400
Amoxicillin
Contour Strips
Fludrocort
Lisinopril
Metformin ER
Oxycod/apap
Lactulose
Culturelle
Aerochamber
Vitamin D
Clopidogrel
Fluticasone
Polyethylene glycol 3350
NF powder

3 (0.50%)
4 (0.70%)
3 (0.50%)
14 (2.50%)
12 (2.20%)
3 (0.50%)
1 (0.20%)
5 (0.90%)
1 (0.20%)
1 (0.20%)
9 (1.60%)
2 (0.40%)
5 (0.90%)
2 (0.40%)
8 (1.40%)
3 (0.50%)
4 (0.70%)

7.18 (8.93)
49.99 (0)
37.13 (0.89)
47.66 (23.67)
9.28 (2.07)
10.59 (19.36)
41.94 (0)
111.55 (-)
16.96 (0)
68.45 (-)
61.29 (-)
6.71 (0)
29.69 (0)
10.82 (0)
26.99 (0)
6.06 (2.62)
16 (2.68)
11.63 (0)

3 (0.50%)
1 (0.20%)
5 (0.90%)
4 (0.70%)
1 (0.20%)
4 (0.70%)
2 (0.40%)
8 (1.40%)
2 (0.40%)
2 (0.40%)
2 (0.40%)
1(0.20%)
1(0.20%)
1(0.20%)
1(0.20%)
1(0.20%)

15.26 (0)
45.54 (-)
8.7 (0)
10.5 (6.35)
40.32 (-)
10 (0)
20
4.90 (0.36)
18.99 (0)
18.96 (0)
18.69 (0)
35.03 (-)
33.74 (-)
32.29 (-)
31.58 (-)
29.76 (-)
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219.95
202.16
188.91
180.54
151.1
150.76
149.97
148.5
142.97
129.86
127.05
125.82
111.55
84.8
68.45
61.29
60.39
59.38
54.1
53.98
48.44
47.97
46.52
45.78
45.54
43.5
42
40.32
40
40
39.18
37.98
37.92
37.38
35.03
33.74
32.29
31.58
29.76

Truplus lanc
Fludricortisone
Phentermine
Spacer inh (optichamber)
Sprintec 28
Trazodone
Multivitamin
Vortex/mask
Klor-con M20
Tri-vitamin
Bayer micrlt
Ibuprofen
Vit B12
Generlac
Pantoprazole
Toothpaste
Fluoxetine
Atenolol
Sod Chloride
Aspirin
Cheratussin AC
Insulin syringe
Citalopram
Topical agents
Fish oil
Glyburid mcr
Vitamin b-6
Niacin

4 (0.70%)
2 (0.40%)
1(0.20%)
1(0.20%)
2 (0.40%)
2 (0.40%)
4 (0.70%)
1(0.20%)
1(0.20%)
1(0.20%)
1(0.20%)
4 (0.70%)
4 (0.70%)
1(0.20%)
1(0.20%)
3 (0.50%)
2 (0.40%)
1(0.20%)
1(0.20%)
5 (0.90%)
1(0.20%)
3 (0.50%)
1(0.20%)
1(0.20%)
1(0.20%)
1(0.20%)
6 (1.10%)
1(0.20%)

6.5 (0)
12 (0)
23.39 (-)
21.29 (-)
10.25 (1.77)
10 (0)
4.99 (0)
19.91 (-)
19.69 (-)
18.99 (-)
17.83 (-)
4 (0)
4 (0)
15.5 (-)
14.45 (-)
4 (0)
5.42 (2.01)
10 (-)
10 (-)
1.95 (0)
9 (-)
2.73 (0)
6 (-)
5.99 (-)
4 (-)
3.52 (-)
0.51 (0)
2.23 (-)

26
24
23.39
21.29
20.5
20
19.96
19.91
19.69
18.99
17.83
16
16
15.5
14.45
12
10.84
10
10
9.75
9
8.19
6
5.99
4
3.52
3.06
2.23

Mean cumulative expenditure: average expenditure for all the observations of a medication paid
by an individual and payments by private insurance, Medicare, Medicaid and other sources,
Total cumulative expenditure: total expenditure for all the observations of a medication paid by
an individual and payments by private insurance, Medicare, Medicaid and other sources, (-): no
standard deviation due to a single observation.
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Table 35: Cumulative expenditure of various drug classes (2010-2014)
Drug class
Respiratory agents
Gastro intestinal agents
Immune modulators
Antibiotics
Medical devices
Pain medications
Drugs used to treat renal failure
Anti-diabetics
Anti-depressants
Anti-allergic agents
Hormone modifiers
Dietary supplements
Anti-inflammatory agents
Anti-hypercholesterolemic agents
Anti-convulsants
Anti-hypertensive agents
Anti-coagulants
Weight loss supplements
Drugs used to treat angioedema
Contraceptives
Tooth paste
Topical agents

Total cumulative expenditure
$ (2010-2014)
85,555.33
17,255.25
14,596.2
14,186.42
5,495.98
2,653.53
2,242.53
1,760.13
1,268.4
849.57
829.44
822.25
636.93
595.84
588
473.15
316.19
173.36
127.05
20.5
12
5.99

Respiratory agents: include bronchodilators, steroids, decongestants, cough suppressants,
expectorants, mucolytics, vasodilators, drugs used to treat asthma, vasoconstrictors; gastro
intestinal agents: include enzyme replacement therapies, proton pump inhibitors to treat stomach
ulcers, laxatives, drugs used to treat gastro esophageal reflux disorders; immune modulators:
includes drugs suppressing or modifying immune responses or immune system to fight infections;
antibiotics: includes aminoglycosides, macrolide antibiotics, tetracyclins, penicillin like
antibiotics, cephalosporins etc.; medical devices: include aerosols, inhalers, glucose monitoring
kits, diabetes testing kit, syringes; pain medications: narcotics; drugs used to treat renal failure:
include medications for kidney stones, dialysis, kidney disease; anti-diabetics: includes drugs
used to treat high blood glucose levels; anti-depressants: drugs used in the treatment of major
depressive disorders and other conditions including anxiety, obsessive compulsive disorder etc.;
anti-allergic agents: includes drugs used to treat allergic conjunctivitis, anti histaminics, local
anesthetics; hormone modifiers: drugs regulating the levels of hormones inside the body; dietary
supplements: includes vitamins, probiotics, low protein diet, supplements used to correct levels
of minerals and nutrients inside the body; anti-inflammatory agents: non-steroidal drugs used to
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treat swelling or inflammation; anti-hypercholesterolemic agents: drugs used to lower
cholesterol levels inside the body; anti-convulsants: drugs used to treat seizures, spasms,
epilepsy, anti-tremor agents, muscle relaxants. Anti-hypertensive agents; anti-coagulants: blood
thinners; weight loss supplements: drugs which promote weight reduction; drugs used to treat
angioedema: hormones or medications used to reduce the swelling of the lower layers of skin
and tissue under the skin or mucous membranes; contraceptives: drugs preventing child birth;
topical agents: creams, ointments or lotions applied externally on skin.

166

Table 36: Sensitivity analysis of cost effectiveness of lumacaftor/ivacaftor
Variable
Flu shot
OGT
Bilirubin
AST
ALT
PFT’S
Fat soluble vitamins
Outpatient visits*
Inpatient stays*
Clinic visits*
Sputum culture
Prob of outpatient visits
Prob of inpatient stays
Prob of clinic visits
Prob of pulmonary
exacerbations
Pulmonary exacerbations
Standard therapy
Drug cost

ICER at
Low
95,014.14
95,013.25
95,011.64
95,011.28
95,011.28
95,009.76
94,979.86
94,935.72
94,910.05
94,905.16
94,959.71
94,934.25
94,910.05
94,905.16
93,791.14

ICER at
high
95,018.43
95,019.32
95,020.93
95,021.28
95,021.28
95,022.81
95,052.71
95,016.28
95,016.28
95,016.28
95,072.86
95,098.29
95,122.51
95,127.41
96,241.42

Difference

93,659.88
87,003.57
70,893.72

96,372.68
103,029
119,138.87

2,712.80
16,025.43
48,245.15

4.29
6.07
9.29
10
10
13.04
72.86
80.56
106.23
111.12
113.14
164.04
212.46
222.24
2,450.28

Sensitivity analysis conducted at low (-25%) and high (+25%); * Sensitivity analysis conducted
at high (-10%) and low (-25%); AST: aspartate aminotransferase test; ALT: alanine
aminotransferase test; PFT: pulmonary lung function test; OGT: oral glucose tolerance test;
prob: probability.
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Table 37: Sensitivity analysis of budget impact of lumacaftor/ivacaftor
Variable

PTMPM cost at
high
6.2069
6.2069

Difference

Flu shot
OGT

PTMPM cost at
Low
6.2066
6.2065

Bilirubin
AST
ALT
PFT’S
Fat soluble vitamins

6.2064
6.2064
6.2064
6.2063
6.2044

6.2070
6.2071
6.2071
6.2072
6.2091

0.0006
0.0007
0.0007
0.0009
0.0048

Outpatient visits*
Inpatient stays *
Clinic visits*
Sputum culture
Prob of outpatient visits
Prob of inpatient stays
Prob of clinic visits
Prob of pulmonary
exacerbations
Pulmonary exacerbations
Drug costs

6.2015
6.1998
6.1995
6.2030
6.2014
6.1998
6.1995
6.1153

6.2067
6.2067
6.2067
6.2104
6.2121
6.2137
6.2140
6.2868

0.0053
0.0069
0.0073
0.0074
0.0107
0.0139
0.0145
0.1715

6.1181
4.1076

6.2953
8.3059

0.1772
4.1983

0.0003
0.0004

Sensitivity analysis conducted at low (-25%) and high (+25%); * Sensitivity analysis conducted
at high (-10%) and low (-25%); AST: aspartate aminotransferase test; ALT: alanine
aminotransferase test; PFT: pulmonary lung function test; OGT: oral glucose tolerance test;
prob: probability.
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